Page last updated: 2024-12-10

silicon

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Occurs in Manufacturing Related Drugs Related Conditions Protein Interactions Research Growth

Description

Silicon: A trace element that constitutes about 27.6% of the earth's crust in the form of SILICON DIOXIDE. It does not occur free in nature. Silicon has the atomic symbol Si, atomic number 14, and atomic weight [28.084; 28.086]. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID5461123
CHEBI ID27573
MeSH IDM0019854

Synonyms (189)

Synonym
silicon dust
un2203
hsdb 5033
un1346
defoamer s-10
silicon metal
silicon, containing more than 99.99 per cent by weight of silicon
silicone
einecs 231-130-8
ccris 6599
Q670
silicium
14si
silizium
silicon atom
silicio
CHEBI:27573 ,
7440-21-3
silicon
si
silicon, wafer (single side polished), <111>, n-type, contains no dopant, diam. x thickness 2 in. x 0.5 mm
silicon, nanopowder, <100 nm particle size (tem), >=98% trace metals basis
silicon, wafer (single side polished), <111>, p-type, contains boron as dopant, diam. x thickness 3 in. x 0.5 mm
silicon, wafer (single side polished), <100>, n-type, contains no dopant, diam. x thickness 2 in. x 0.5 mm
silicon, wafer (single side polished), <111>, n-type, contains no dopant, diam. x thickness 3 in. x 0.5 mm
silicon, wafer (single side polished), contains phosphorus as dopant, <111>, n-type, diam. x thickness 2 in. x 0.5 mm
silicon, wafer (single side polished), <100>, n-type, contains phosphorus as dopant, diam. x thickness 2 in. x 0.5 mm
silicon, wafer, <111>, p-type, contains boron as dopant, diam. x thickness 2 in. x 0.3 mm
silicon, wafer (single side polished), <100>, n-type, contains no dopant, diam. x thickness 3 in. x 0.5 mm
silicon, wafer (single side polished), <100>, n-type, contains phosphorus as dopant, diam. x thickness 3 in. x 0.5 mm
silicon, wafer (single side polished), <100>, p-type, contains boron as dopant, diam. x thickness 2 in. x 0.5 mm
silicon, wafer (single side polished), <100>, p-type, contains boron as dopant, diam. x thickness 3 in. x 0.5 mm
silicon, powder, -325 mesh, 99% trace metals basis
silicon, powder, -60 mesh, 99.999% trace metals basis
silicon, pieces, 99.95% trace metals basis
AKOS004909675
silicon 28
silane, compressed [un2203] [flammable gas]
silicon powder, amorphous [un1346] [flammable solid]
silicon, elemental
ec 231-130-8
z4152n8iui ,
unii-z4152n8iui
silicon powder, amorphous
90337-93-2
silane [mi]
silane [hsdb]
silicon [who-dd]
silicon [mart.]
silicon [ii]
silicon [mi]
silicon [inci]
silicon, elemental [hsdb]
silicon (si), >98%
silane, 7.0 - 7.5% in argon
silicon powder, crystalline, -100+200 mesh
silicon powder (nanocrystalline)
silicon powder (amorphous)
AKOS024438062
silicon powder
silicon powder, crystalline, aps c=100nm
silicon lump, 10cm (3.9in) & down
silicon rod, 0.828cm (0.326in) dia
silicon powder, crystalline, -140 mesh
silicon rod, 5.08cm (2.0in) dia
silicon powder, crystalline, -100+325 mesh
silicon powder, crystalline, -325 mesh
silicon plate, 12.5mm (0.5in) thick
silicon sputtering target, 50.8mm (2.0in) dia x 3.18mm (0.125in) thick
silicon powder, crystalline, -100 mesh
silicon plate, 6.35mm (0.25in) thick
silicon rod, 2.5cm (0.98in) dia
silicon powder, crystalline, aps <=50nm
silicon lump, 15cm (5.9in) & down
silicon plate, 9.5mm (0.37in) thick
silicon sputtering target, 50.8mm (2.0in) dia x 6.35mm (0.250in) thick
silicon, sputtering target, diam. x thickness 2.00 in. x 0.25 in., 99.999% trace metals basis
silicon, nanopowder, <100 nm (bet), <3% oxygen passivation
silicon standard for aas, ready-to-use, in hno3: hf
mfcd00085311
mfcd00011228
silicon chips
silicon random pieces
silicon metal powder si grade ax 05 (h?gan?s)
silicon metal powder si grade ax 20 (h?gan?s)
silicon metal powder si grade ax 10 (h?gan?s)
silicon powder, nodular, aps 1-5 micron
silicon lump, 0.1-2.5cm (0.04-1.0in)
silicon slugs, 9.5mm (0.375in) dia x 9.5mm (0.375in) length
silicon, cp
silicon, single crystal, -100, n-type, phosphorus doped, diameter 150mm, length 0.65mm, 100%
silicon, rod, 100mm, diameter 25mm, crystalline, 100%
silicon, powder, max. particle size 45 micron, weight 50 g, high purity 99.998%
silicon, powder, 45 max. part. size (micron), weight 10 g, high purity 99.999%
silicon, lump, 25 mm max. lump size, weight 200 g, purity 99.999%
silicon, lump, 25 mm max. lump size, weight 50 g, purity 99.99%
silicon, rod, 20 mm diameter, length 80 mm, purity 99.999%
silicon, rod, 50mm, diameter 5.0mm, crystalline, 100%
silicon, single crystal, -111, size, thickness 0.4 mm
silicon, sphere, 20pcs, diameter 2.0mm, precision sphere grade 25
silicon, powder, 45 max. part. size (micron), weight 100 g, purity 99.95%
silicon, rod, 100mm, diameter 10.0mm, single crystal - random orientation, 100%
silicon, powder, 150 max. part. size (micron), weight 2000 g, purity 97.5%
silicon, rod, length 100 mm, 20 mm diameter, purity 99.999%
silicon, powder, 45 max. part. size (micron), weight 50 g, purity 99.5%
silicon, lump, 5 mm max. lump size, weight 500 g, purity 99.99%
silicon, sphere, 50pcs, diameter 2.0mm, precision sphere grade 25
silicon, powder, max. particle size 150 micron, weight 100 g, purity 97.5%
silicon, powder, max. particle size 45 micron, weight 100 g, purity 99.5%
silicon, rod, 20 mm diameter, length 50 mm, purity 99.999%
silicon, single crystal, -111, p-type, boron doped, diameter 57mm, length 1.0mm, 100%
silicon, rod, 50mm, diameter 2.0mm, crystalline, 100%
silicon, powder, 150 max. part. size (micron), weight 1000 g, purity 97.5%
silicon, powder, 45 max. part. size (micron), weight 50 g, purity 99.95%
silicon, lump, 25 mm max. lump size, weight 50 g, purity 99.95%
silicon, disks, 15.9mm, thickness 0.38mm, single crystal, n-type, 100%
silicon, sheet, 14x14mm, thickness 1.0mm, single crystal, -100, 100%
silicon, rod, 50mm, diameter 5mm, single crystal, -111, 99.999%
silicon, lump, 25 mm max. lump size, weight 100 g, purity 99.999%
silicon, single crystal, -100, n-type, phosphorus doped, diameter 76.2mm, length 2.0mm, 100%
silicon, single crystal, -111, n-type, phosphorus doped, diameter 76.2mm, length 0.50mm, 100%
silicon, sheet, 10x10mm, thickness 0.5mm, single crystal, -100, 100%
silicon, lump, 25 mm max. lump size, weight 100 g, purity 99.95%
silicon, rod, 50mm, diameter 6mm, single crystal, -111, 99.999%
silicon, sheet, 14x14mm, thickness 1.0mm, single crystal, -111, 100%
silicon, sphere, 10pcs, diameter 2.0mm, precision sphere grade 25
silicon, lump, 25 mm max. lump size, weight 200 g, purity 99.95%
silicon, lump, 25 mm max. lump size, weight 200 g, purity 99.99%
silicon, single crystal, -100, n-type, phosphorus doped, diameter 76.2mm, length 0.38mm, 100%
silicon, rod, 25mm, diameter 3.15mm, single crystal - random orientation, 100%
silicon, lump, 5 mm max. lump size, weight 100 g, purity 99.99%
silicon, rod, 100mm, diameter 2.0mm, crystalline, 100%
silicon, rod, 100mm, diameter 12.7mm, single crystal - random orientation, 100%
silicon, lump, 25 mm max. lump size, weight 50 g, purity 99.999%
silicon, lump, 25 mm max. lump size, weight 500 g, purity 99.95%
silicon, single crystal, -111, n-type, phosphorus doped, diameter 76.2mm, length 0.38mm, 100%
silicon, powder, 150 max. part. size (micron), weight 200 g, purity 97.5%
silicon, lump, 5 mm max. lump size, weight 50 g, purity 99.99%
silicon, single crystal, -111, n-type, phosphorus doped, diameter 76.2mm, length 0.75mm, 100%
silicon, rod, 25 mm diameter, length 150 mm, purity 99.999%
silicon, sphere, 0.48 mm diameter, 50 pcs, tolerance +/-2.5um
silicon, sheet, 10x10mm, thickness 0.6mm, single crystal, -100, 100%
silicon, lump, 25 mm max. lump size, weight 500 g, purity 99.99%
silicon, rod, 40mm, diameter 20mm, single crystal, -100, 99.999%
silicon, powder, max. particle size 150 micron, weight 500 g, purity 97.5%
silicon, sheet, 40x40mm, thickness 3.0mm, single crystal, p-type, 100%
silicon, sheet, 25x25mm, thickness 1.0mm, single crystal, -100, 100%
silicon, lump, 25 mm max. lump size, weight 100 g, purity 99.99%
silicon, rod, 80mm, diameter 20mm, single crystal, -100, 99.999%
silicon, powder, 45 max. part. size (micron), weight 100 g, high purity 99.998%
silicon, powder, 45 max. part. size (micron), purity 99.95%, weight 200 g
silicon, rod, 25mm, diameter 2.0mm, crystalline, 100%
silicon, rod, 50mm, diameter 3.15mm, single crystal - random orientation, 100%
silicon, powder, max. particle size 45 micron, weight 200 g, purity 99.5%
silicon, rod, 50mm, diameter 5mm, single crystal, -100, 99.999%
silicon, single crystal, -111, p-type, boron doped, diameter 76.2mm, length 0.38mm, 100%
silicon, rod, 100mm, diameter 5.0mm, crystalline, 100%
silicon, single crystal, -100, p-type, boron doped, diameter 76.2mm, length 0.38mm, 100%
silicon, rod, 40mm, diameter 20mm, single crystal, -111, 99.999%
silicon, powder, 45 max. part. size (micron), weight 20 g, high purity 99.998%
silicon, sphere, 0.48 mm diameter, 10_pcs, tolerance +/-2.5um
silicon, sphere, 0.48 mm diameter, 20 pcs, tolerance +/-2.5um
silicon, disks, 13mm, thickness 0.38mm, single crystal, 100%
silicon, lump, 5 mm max. lump size, weight 200 g, purity 99.99%
silicon, rod, 10mm, diameter 2.0mm, crystalline, 100%
silicon metal, nist(r) srm(r) 57b
silicon, nist(r) srm(r) 640e, powder, line position and line shape standard for powder diffraction
silicon, 99.0%
DB12982
DTXSID0051441 ,
silicon nanopowder
AMY37004
silicon hollow cathode lamp: 2.0 diameter, 4-pin, cableless
silicon hollow cathode lamp: 2.0 diameter, 9-pin, non-coded
silicon hollow cathode lamp: 1.5 diameter, 2-pin, non-coded
dtxcid5030038
silicon (mart.)
silicon (ii)
sulfur-free silicon standard: si @ 1000 microg/g in hydrocarbon oil
silicon standard: si @ 5000 microg/g in hydrocarbon oil
silicon standard: si @ 1000 microg/ml in h2o, tr. f-
silicon aa standard: si @ 1000 microg/ml in h2o, tr. f-
silicon standard: si @ 1000 microg/g in hydrocarbon oil
sulfur-free silicon concentrate: si @ approx. 18 wt% in hydrocarbons
silicon standard: si @ 10000 microg/ml in h2o, tr. f-
PD058322
silicon - si @ 1000 microg/ml in h2o, tr. f-
silicon - si @ 5000 microg/g in hydrocarbon oil
silicon - si @ 1000 microg/g in hydrocarbon oil

Research Excerpts

Toxicity

Soil contamination with toxic heavy metals (such as arsenic (As) is becoming a serious global problem. Silicon (Si) and sodium hydrosulfide (NaHS) has been found effective in enhancing plant tolerance against biotic and abiotic stresses including the As toxicity.

ExcerptReferenceRelevance
"A controlled clinical trial of the anti-epileptic efficacy and toxic side effects of diphenylsilanediol was conducted on 24 client-owned epileptic dogs."( Clinical evaluation of the new compound diphenylsilanediol for ani-epileptic efficacy and toxicity.
Chandler, ML; Cunningham, JG; Ford, RB; Gifford, JA; Hulce, VD; LeVier, RR, 1981
)
0.26
"The prenatal toxic effects of contaminated vacuum pump oil (Sample A) and solid waste products (Samples B and C) originating from aluminum plasma etching processes in semiconductor manufacturing were investigated."( Toxicological investigations in the semiconductor industry: III: Studies on prenatal toxicity caused by waste products from aluminum plasma etching processes.
Bauer, S; Herzschuh, R; Pelzing, M; Scheufler, H; Schmidt, R; Wolff, L,
)
0.13
" Whereas the toxic effects of AI within this population are clearly established, little is known on the role of Si in the development/protection of particular dialysis-related diseases."( Al and Si: their speciation, distribution, and toxicity.
D'Haese, PC; de Broe, ME; van Landeghem, GF, 1998
)
0.3
"A new forceps suitable for the safe and easier insertion of a silicon catheter into the subdural space is described."( A new forceps for the safe and easier insertion of subdural catheter: technical note.
Birbilis, T; Bockermann, V, 1998
)
0.3
"It is widely believed that using the "tunneling" procedure during pancreatoduodenectomy is a safe maneuver because the anterior tributaries of the portal vein (PV) are absent or very rare."( Anterior tributaries of the portal vein at the superior margin of the pancreas: is "tunneling" procedure safe during pancreatic surgery?
Nagai, M; Nobori, M; Nokubi, M; Sakamoto, Y; Suzuki, Y; Tanaka, N; Tsukamoto, T, 2000
)
0.31
"Toxicity varied but RC Sealer and GuttaFlow were the least toxic new sealers."( Cytotoxicity of new resin-, calcium hydroxide- and silicone-based root canal sealers on fibroblasts derived from human gingiva and L929 cell lines.
Dahl, JE; Eldeniz, AU; Mustafa, K; Ørstavik, D, 2007
)
0.34
" No adverse changes were observed in animals exposed to any of the SAS at 1mg/m(3)."( Five-day inhalation toxicity study of three types of synthetic amorphous silicas in Wistar rats and post-exposure evaluations for up to 3 months.
Arts, JH; Duistermaat, E; Junker, K; Kuper, CF; Muijser, H, 2007
)
0.34
" plantarum medium; acidification resulting from metabolic activity was inhibited by the toxic activity of the surfactant."( Surfactant cytotoxicity assay based on a silicon transducer.
Seki, A; Tokita, K, 2009
)
0.35
" Collectively, these data provide evidence of a safe intravenous administration of S1MPs as a drug delivery carrier."( In vivo evaluation of safety of nanoporous silicon carriers following single and multiple dose intravenous administrations in mice.
Amra, S; Bhavane, R; Chiappini, C; Ewing, A; Fakhoury, JR; Ferrari, M; Fidler, IJ; Godin, B; Gu, J; Li, Q; Liu, X; Nieves-Alicea, R; Tanaka, T, 2010
)
0.36
" The present study is focused on the detection of toxic matter using a novel silicon-based MFC."( Silicon-based microfabricated microbial fuel cell toxicity sensor.
Dávila, D; Esquivel, JP; Mas, J; Sabaté, N, 2011
)
0.37
" We therefore compared the toxic effects of classroom, outdoor, and residential PM(10)."( Toxicity and elemental composition of particulate matter from outdoor and indoor air of elementary schools in Munich, Germany.
Behrendt, H; Buters, JT; Dietrich, S; Fromme, H; Jörres, RA; Nowak, D; Oeder, S; Pusch, G; Schierl, R; Schober, W; Weichenmeier, I, 2012
)
0.38
" This study provides fundamental evidence for the safe application and further modification of silicon nanoparticles, which could broaden their application as cell markers in living systems and in micelle encapsulated drug delivery systems."( Uptake and toxicity studies of poly-acrylic acid functionalized silicon nanoparticles in cultured mammalian cells.
Bao, Y; Chao, Y; Coxon, PR; Jayasooriya, UA; Wang, Q; Zhang, X, 2012
)
0.38
" The adverse effects of Cd on plant growth were alleviated by the exogenous application of Si."( Alleviation of cadmium toxicity by silicon is related to elevated photosynthesis, antioxidant enzymes; suppressed cadmium uptake and oxidative stress in cotton.
Ali, S; Farooq, MA; Hameed, A; Iqbal, Z; Ishaque, W; Mahmood, K, 2013
)
0.39
" However, concerns about their adverse effects are growing due to the association between exposure to certain nanosized particles and cardiovascular events."( Injected nanoparticles: the combination of experimental systems to assess cardiovascular adverse effects.
Borzykh, AA; Eletskii, AV; Herzig, KH; Järvinen, K; Kauppinen, EI; Lehto, VP; Lobach, AS; Raula, J; Riikonen, J; Salonen, J; Smirin, BV; Tarasova, OS; Tavi, P; Vlasova, MA, 2014
)
0.4
"Non-reinforced and laser safe ETTs were suspended in a mechanical model imitating endoscopic airway surgery."( Prevention of airway fires: testing the safety of endotracheal tubes and surgical devices in a mechanical model.
Roy, S; Smith, LP,
)
0.13
" The CO2 laser could not ignite a laser safe ETT under any conditions, unless it struck the non-reinforced distal tip of the ETT."( Prevention of airway fires: testing the safety of endotracheal tubes and surgical devices in a mechanical model.
Roy, S; Smith, LP,
)
0.13
" Anatomical observations of leaf and root revealed that Cr(VI) affected internal structures while Si played a role in protection from toxic effects."( Silicon-mediated alleviation of Cr(VI) toxicity in wheat seedlings as evidenced by chlorophyll florescence, laser induced breakdown spectroscopy and anatomical changes.
Chauhan, DK; Kishore Dubey, N; Prasad, SM; Rai, AK; Singh, VP; Tripathi, DK, 2015
)
0.42
" The key mechanisms evoked include reducing active heavy metal ions in growth media, reduced metal uptake and root-to-shoot translocation, chelation and stimulation of antioxidant systems in plants, complexation and co-precipitation of toxic metals with Si in different plant parts, compartmentation and structural alterations in plants and regulation of the expression of metal transport genes."( Mechanisms of silicon-mediated alleviation of heavy metal toxicity in plants: A review.
Abbas, F; Adrees, M; Ali, S; Farid, M; Ibrahim, M; Irshad, MK; Qayyum, MF; Rizwan, M; Zia-Ur-Rehman, M, 2015
)
0.42
"Exploration and expansion of the chemistries involving toxic or carcinogenic reagents are severely limited by the health hazards their presence poses."( Micro-total envelope system with silicon nanowire separator for safe carcinogenic chemistry.
Jang, S; Kim, DP; Ko, DH; Min, KI; Singh, AK; Vishwakarma, NK, 2016
)
0.43
") were found to be within safe limits 3 h, 24 h, 48 h and 7 days after the administration."( Ultrapure laser-synthesized Si-based nanomaterials for biomedical applications: in vivo assessment of safety and biodistribution.
Al-Kattan, A; Baati, T; Braguer, D; Chaspoul, F; Esteve, MA; Hammami, M; Kabashin, AV; Njim, L; Ryabchikov, Y; Sentis, M, 2016
)
0.43
" MTA showed the least toxic effect."( Cytotoxicity of modified glass ionomer cement on odontoblast cells.
Chen, S; Engqvist, H; Lan, W; Mestres, G; Xia, W, 2016
)
0.43
" Moreover, we demonstrate that there are no toxic effects of SiNPs on the cell metabolic activity and integrity of the plasma membrane."( In vitro cellular behaviors and toxicity assays of small-sized fluorescent silicon nanoparticles.
Cao, Z; Chu, B; He, S; He, Y; Hu, Z; Peng, F; Su, Y; Zhong, Y, 2017
)
0.46
" We found that FeSSi particles with Cd sorbed onto them are an order of magnitude more toxic than FeSSi alone."( Remediation of Cadmium Toxicity by Sulfidized Nano-Iron: The Importance of Organic Material.
Adeleye, AS; Keller, AA; Nisbet, RM; Stevenson, LM; Su, Y; Zhang, Y, 2017
)
0.46
"Cadmium (Cd) is a toxic element that poses a great threat to human health, while silicon (Si) is a beneficial element and has been shown to have a mitigation effect on plants under Cd toxicity."( Silicon alleviates cadmium toxicity in wheat seedlings (Triticum aestivum L.) by reducing cadmium ion uptake and enhancing antioxidative capacity.
Han, D; Li, X; Liu, Y; Shi, Z; Yang, S; Zhang, B; Zhou, Z, 2018
)
0.48
" In many respects, the Al₂O₃-NP was found to be the most toxic species alone and the most dangerous component of the combinations studied."( Combined Subchronic Toxicity of Aluminum (III), Titanium (IV) and Silicon (IV) Oxide Nanoparticles and Its Alleviation with a Complex of Bioprotectors.
Bushueva, TV; Gurvich, VB; Katsnelson, BA; Klinova, SV; Makeyev, OH; Meshtcheryakova, EY; Minigalieva, IA; Panov, VG; Privalova, LI; Sakhautdinova, RR; Shishkina, EV; Shur, VY; Solovyeva, SN; Sutunkova, MP; Valamina, IE; Varaksin, AN, 2018
)
0.48
"Cadmium (Cd) is toxic to plants and animals, making it necessary to develop strategies that seek to reduce its introduction into food chains."( Selenium and silicon reduce cadmium uptake and mitigate cadmium toxicity in Pfaffia glomerata (Spreng.) Pedersen plants by activation antioxidant enzyme system.
Bernardy, D; Bernardy, K; Dorneles, AOS; Dressler, VL; Pereira, AS; Possebom, G; Rossato, LV; Sasso, VM; Tabaldi, LA, 2018
)
0.48
" In vivo experiments of the levan represent nontoxicity and biocompatibility without any adverse reactions."( Biosafe, Eco-Friendly Levan Polysaccharide toward Transient Electronics.
Choi, CH; Hwang, SW; Jo, YJ; Kim, TI; Ko, GJ; Kwon, KY; Lee, JS; Lee, S; Sunwoo, SH, 2018
)
0.48
"The inability of traditional chemotherapeutics to reach cancer tissue reduces the treatment efficacy and leads to adverse effects."( Designed inorganic porous nanovector with controlled release and MRI features for safe administration of doxorubicin.
Al-Jamal, KT; Backholm, M; Fan, L; Kettunen, MI; Lehto, VP; Näkki, S; Nissinen, T; Rantanen, J; Ras, RHA; Wang, JT; Wu, J; Xu, W, 2019
)
0.51
"Cadmium (Cd) is a highly toxic heavy metal for both animals and plants."( Effects of boron, silicon and their interactions on cadmium accumulation and toxicity in rice plants.
Chen, D; Jia, L; Lin, X; Lin, Y; Long, J; Song, Y; Xue, R; Zeng, R, 2019
)
0.51
" This study provided new evidence that Si and NO have a strong joint effect on alleviating the adverse effects of Cd toxicity by decreasing Cd uptake and accumulation."( Combined application of silicon and nitric oxide jointly alleviated cadmium accumulation and toxicity in maize.
Deng, X; Du, S; Gong, D; Liu, X; Wang, S; Yin, L; Zhang, Z, 2020
)
0.56
" The addition of Si did not reduce the concentrations of Mn in accumulations despite seeming to reduce its adverse effects."( Time-resolved laboratory micro-X-ray fluorescence reveals silicon distribution in relation to manganese toxicity in soybean and sunflower.
Blamey, FPC; Casey, LW; Kopittke, PM; van der Ent, A, 2020
)
0.56
" A substantial part of the review will be focused on in vitro toxicity, in which the type of QDs is combined with their adverse effect and toxic mechanism."( Toxicity of different types of quantum dots to mammalian cells in vitro: An update review.
Liu, N; Tang, M, 2020
)
0.56
" However, Si and MeJA applied alone or in combination significantly ameliorated the above-mentioned adverse effects induced by Cd."( Effect of exogenous silicon and methyl jasmonate on the alleviation of cadmium-induced phytotoxicity in tomato plants.
Guo, J; Hua, L; Li, H; Li, X; Ren, X; Sun, Y; Wei, T; Yashir, N, 2021
)
0.62
" The bioassays indicated that polycrystalline SBSC (p-Si) and monocrystalline SBSC (m-Si) leachates were more toxic to fish embryos than the PSC leachates and that water fleas were sensitive to m-Si leachates, but less sensitive to PSC and p-Si leachates."( Comparative toxicity of potential leachates from perovskite and silicon solar cells in aquatic ecosystems.
An, YJ; Chae, H; Han, S; Jeong, SW; Kim, L; Kwak, JI; Lee, TY; Panthi, G, 2021
)
0.62
" Thus, we evaluated the beneficial roles of alone or/and combine applications of SA and Si in mitigating the toxic effects of Cr in the leaves and roots of rice (Oryza sativa) seedlings."( Salicylic acid underpins silicon in ameliorating chromium toxicity in rice by modulating antioxidant defense, ion homeostasis and cellular ultrastructure.
Azhar, W; Hamid, Y; Hussain, S; Khan, AR; Salam, A; Shah, AM; Sheteiwy, MS; Ulhassan, Z; Yang, S; Zhou, W, 2021
)
0.62
"The inessential heavy metal/loids cadmium (Cd) and arsenic (As), which often co-occur in polluted paddy soils, are toxic to rice."( Comparative physiological and transcriptomic analyses illuminate common mechanisms by which silicon alleviates cadmium and arsenic toxicity in rice seedlings.
Chen, H; Gong, X; Li, F; Liang, X; Liu, C; Liu, X; Reinfelder, JR; Sun, C; Yi, J; Zhang, S; Zhao, J, 2021
)
0.62
" Both arsenic (As) and silicon (Si) are metalloids - while the first one is toxic in general, the latter one is considered as beneficial for plants suffering from various kinds of stresses."( Effect of silicon on root growth, ionomics and antioxidant performance of maize roots exposed to As toxicity.
Kollárová, K; Mišúthová, A; Slováková, Ľ; Vaculík, M, 2021
)
0.62
" Antimony (Sb) is a non-essential metalloid causing toxic effects in plants."( Silicon alleviates antimony phytotoxicity in giant reed (Arundo donax L.).
Shetty, R; Vaculík, M; Vidya, CS; Weidinger, M, 2021
)
0.62
" Silicon (Si) and arbuscular mycorrhizal (AM) fungi play significant roles in alleviating adverse effects of As stress."( Arbuscular mycorrhizae and silicon alleviate arsenic toxicity by enhancing soil nutrient availability, starch degradation and productivity in Cajanus cajan (L.) Millsp.
Bhalla, S; Garg, N, 2021
)
0.62
"Nano-materials ameliorate the adverse effect of salinity stress on the physiological and biochemical processes in plants."( The potential of foliar application of nano-chitosan-encapsulated nano-silicon donor in amelioration the adverse effect of salinity in the wheat plant.
Hajihashemi, S; Kazemi, S, 2022
)
0.72
"In the present study, the beneficial role of NC, NS, and NC-NS application, particularly NC-NS, in alleviating the adverse effect of salinity stress on antioxidant systems and osmotic adjustment in wheat is well documented."( The potential of foliar application of nano-chitosan-encapsulated nano-silicon donor in amelioration the adverse effect of salinity in the wheat plant.
Hajihashemi, S; Kazemi, S, 2022
)
0.72
"Cadmium (Cd) is a widely distributed heavy metal that is toxic to plants and humans."( Silicon-enhanced tolerance to cadmium toxicity in soybean by enhancing antioxidant defense capacity and changing cadmium distribution and transport.
Cai, Z; Cheng, Y; Lian, T; Ma, Q; Nian, H; Xian, P; Yang, Y; Zhou, Q, 2022
)
0.72
" Hexavalent chromium [Cr(VI)], the most toxic form of Cr, brings about changes in plant processes at morpho-physiological and biochemical levels."( Silicon Palliates Chromium Toxicity through the Formation of Root Hairs in Rice (Oryza sativa) Mediated by GSH and IAA.
Corpas, FJ; Kandhol, N; Kumar, A; Rai, P; Sahi, S; Sharma, S; Singh, VP; Tripathi, DK, 2023
)
0.91
"Excess copper (Cu) causes the toxic effects in plants and health hazards to humans."( Interactive effect of silicon and nitric oxide effectively contracts copper toxicity in
Amooaghaie, R; Bakhtiari, S; Pirooz, P, 2023
)
0.91
"Soil contamination with toxic heavy metals (such as arsenic (As)) is becoming a serious global problem due to rapid development of social economy, although the use of silicon (Si) and sodium hydrosulfide (NaHS) has been found effective in enhancing plant tolerance against biotic and abiotic stresses including the As toxicity."( Application of silicon and sodium hydrosulfide alleviates arsenic toxicity by regulating the physio-biochemical and molecular mechanisms of Zea mays.
Alatawi, A; Ali, S; Alshegaihi, RM; Asghar, MA; Elsharkawy, MM; Fahad, S; Javed, S; Marc, RA; Mfarrej, MFB; Mumtaz, S; Yasin, G, 2023
)
0.91
"Emergence of trace elements at potentially toxic concentrations in the environment has become a global issue in recent times."( Emergence of toxic trace elements in plant environment: Insights into potential of silica nanoparticles for mitigation of metal toxicity in plants.
Dwibedi, V; George, N; Yadav, M, 2023
)
0.91
"Aluminum (Al) is highly toxic to plants, since it causes stress and inhibits plant growth."( Silicon as an attenuator of the toxic effects of aluminum in Schinus terebinthifolius plants.
Aguilar, MVM; Azevedo, TD; Lovato, LR; Mattos, JPO; Nicoloso, FT; Rosa, FCR; Tabaldi, LA; Valsoler, DV; Wertonge, GS, 2023
)
0.91

Pharmacokinetics

The terminal half-life of free silicon in the aqueous was 30 min and 92 min in the vitreous. The mean plasma silicon Cmax values (+/- S.hr/L) were revealed.

ExcerptReferenceRelevance
"The pharmacodynamic effect of a homologous series of aminomethyldimethyl-(methoxyphenyl)-silane derivatives have been tested on isolated guinea-pig left atria."( Pharmacodynamic specification and membrane stabilising action of a homologous series of silasympathomimetics.
Greeff, K; Schlieper, P; Tawfik, H, 1986
)
0.27
" The microdialysis revealed the terminal half-life of free silicon in the aqueous was 30 min and 92 min in the vitreous; the AUC for aqueous accounted for 38% of the AUC for vitreous."( Ocular silicon distribution and clearance following intravitreal injection of porous silicon microparticles.
Cheng, L; Freeman, WR; Hou, H; Nieto, A; Sailor, MJ, 2013
)
0.39
" Pharmacokinetic analysis demonstrated a vitreous half-life of 29 days with a maximum DNR concentration of 178 ng/mL and a minimum concentration of 29 ng/mL at day 84."( A Novel Approach of Daunorubicin Application on Formation of Proliferative Retinopathy Using a Porous Silicon Controlled Delivery System: Pharmacodynamics.
Cheng, L; Freeman, WR; Hou, H; Huffman, K; Rios, S; Sailor, MJ, 2015
)
0.42

Compound-Compound Interactions

modified differential lysis method combined with silicon bead method can be used in extraction of sperm DNA from mixed stain. This research was developed to investigate if inoculation with Azospirillum brasilense in combination with silicon can enhance N use efficiency (NUE) in maize.

ExcerptReferenceRelevance
"Imaging ellipsometry was combined with electrochemical methods for studying electrostatic interactions of protein and solid surfaces."( Influence of electrostatic interaction on fibrinogen adsorption on gold studied by imaging ellipsometry combined with electrochemical methods.
Jin, G; Yu, Y, 2005
)
0.33
"In this work, we introduce a maskless, resist-free rapid prototyping method to fabricate three-dimensional structures using electron beam induced deposition (EBID) of amorphous carbon (aC) from a residual hydrocarbon precursor in combination with metal-assisted chemical etching (MaCE) of silicon."( Maskless and resist-free rapid prototyping of three-dimensional structures through electron beam induced deposition (EBID) of carbon in combination with metal-assisted chemical etching (MaCE) of silicon.
Fedorov, AG; Henry, MR; Hildreth, OJ; Kim, SK; Kulkarni, D; Rykaczewski, K; Tsukruk, VV; Wong, CP, 2010
)
0.36
"The experiments carried out on male rats have demonstrated that the primary prophylactic application of drinking sulfate mineral water (MW) in combination with such microelements as zinc and silicon results in a more pronounced decrease of the magnitude of alterations in the liver, thymus, and blood hormonal spectrum under the action of immobilization stress than the application of mineral water alone."( [The application of drinking mineral water in combination with zinc and silicon in rats undergoing immobilization stress].
Bobkova, AS; Korolev, IuN; Mikhaĭlik, LV,
)
0.13
"The present experiments carried out on outbred male rats have demonstrated that the treatment with drinking mineral water in combination with microelements, zinc and silicon, significantly increased resistance of their cultured Sertoli cells to the stressful impact of a single immobilization event and promoted the development of intracelular adaptive and protective reactions."( [Ultrastructural changes of sertoli cells in rat testicles treated with drinking mineral water in combination with microelements, zinc and silicon, under stress conditions].
Geniatulina, MS; Korolev, IuN; Nikulina, LA,
)
0.13
"To extract sperm DNA from mixed stain by the modified differential lysis method combined with silicon bead method and to evaluate its application value."( [Extraction of sperm DNA from mixed stain by the modified differential lysis method combined with silicon bead method].
Han, HJ; Jia, DT; Lu, DR; Yang, GY; Yang, M; Yi, H; Zhang, YH, 2014
)
0.4
" The sperm DNA was extracted by the modified method combined with silicon bead method, then genotyped with the Identifiler Kit, and compared with the results of genotyping by the conventional differential lysis method as control."( [Extraction of sperm DNA from mixed stain by the modified differential lysis method combined with silicon bead method].
Han, HJ; Jia, DT; Lu, DR; Yang, GY; Yang, M; Yi, H; Zhang, YH, 2014
)
0.4
"08% through the modified method combined with silicon bead method."( [Extraction of sperm DNA from mixed stain by the modified differential lysis method combined with silicon bead method].
Han, HJ; Jia, DT; Lu, DR; Yang, GY; Yang, M; Yi, H; Zhang, YH, 2014
)
0.4
"The modified differential lysis method combined with silicon bead method can be used in extraction of sperm DNA from mixed stain."( [Extraction of sperm DNA from mixed stain by the modified differential lysis method combined with silicon bead method].
Han, HJ; Jia, DT; Lu, DR; Yang, GY; Yang, M; Yi, H; Zhang, YH, 2014
)
0.4
" Large-scale recordings of neuronal spiking combined with optogenetic perturbation of identified individual neurons has emerged as a suitable method for such tasks in behaving animals."( Tools for probing local circuits: high-density silicon probes combined with optogenetics.
Berényi, A; Buzsáki, G; Khodagholy, D; Kipke, DR; Stark, E; Wise, KD; Yoon, E, 2015
)
0.42
"We report on highly disordered array of Au coated silicon nanowires (Au/SiNWs) as surface enhanced Raman scattering (SERS) probe combined with electrochemical detection for biosensing applications."( Disordered array of Au covered Silicon nanowires for SERS biosensing combined with electrochemical detection.
Convertino, A; Maiolo, L; Mussi, V, 2016
)
0.43
" This research was developed to investigate if inoculation with Azospirillum brasilense in combination with silicon (Si) can enhance N use efficiency (NUE) in maize."( Can silicon applied to correct soil acidity in combination with Azospirillum brasilense inoculation improve nitrogen use efficiency in maize?
Boleta, EHM; Buzetti, S; Filho, MCMT; Galindo, FS; Lazarini, E; Pagliari, PH; Rodrigues Nogueira, TA; Rodrigues, WL; Rosa, PAL; Santini, JMK, 2020
)
0.56
" The present study aimed to quantify the ability of a digital TOF-PET/CT scanner combined with BPL reconstruction to detect small lesions, and to determine the optimal penalization factor (β) in BPL to accurately detect such lesions."( Detection of sub-centimeter lesions using digital TOF-PET/CT system combined with Bayesian penalized likelihood reconstruction algorithm.
Hiratsuka, S; Ishii, K; Kamitaka, Y; Kobayashi, R; Masubuchi, M; Miwa, K; Miyaji, N; Nemoto, R; Wagatsuma, K; Yamaguchi, M; Yamao, T; Yoshii, T, 2020
)
0.56
"A field experiment involving eight treatments with water management combined with leaf spraying silicon fertilizer was conducted in a paddy field heavily contaminated with Cd (2."( [Effects of Different Treatments with Water Management Combined with Leaf Spraying Silicon Fertilizer on Cd Accumulation in Rice].
Gu, JF; Hu, YD; Huang, F; Huo, Y; Liao, BH; Liu, J; Liu, JW; Wei, BY; Zhang, JY; Zhou, H, 2020
)
0.56
" In this study, we conducted a consecutive 3-year field experiment to explore the effects of N fertilizer reduction combined with straw biochar application on rice yield, Si and N nutrition."( Effects of N fertilizer reduction combined with straw biochar application on the yield, Si, and N nutrition of double-cropping rice.
Cai, KZ; Chen, HL; Chen, YG; Li, TX; Liu, R; Ning, CC; Tian, JH, 2023
)
0.91
" Previous studies have indicated that the AgNPs/PSB composite SERS substrate, combined with machine learning algorithms, has achieved promising classification results in disease diagnosis."( Application of serum SERS technology combined with deep learning algorithm in the rapid diagnosis of immune diseases and chronic kidney disease.
Chen, C; Chen, X; Han, S; Li, Z; Luo, C; Lv, X; Wu, L; Yang, J, 2023
)
0.91

Bioavailability

The bioavailability of silicon in stabilized orthosilicic acid was investigated in a double blind, placebo controlled supplementation study. Replacing carbon with silicon in pharmaceuticals and pesticides has shown to result in positive effects.

ExcerptReferenceRelevance
" These species mediate the bioavailability and cellular toxicity of aluminium."( The interrelationship between silicon and aluminium in the biological effects of aluminium.
Birchall, JD, 1992
)
0.28
" The purpose of this study was to compare the oral bioavailability of silicon and aluminum from Zeolite A, sodium aluminosilicate, magnesium trisilicate, and aluminum hydroxide in dogs."( Pharmacokinetic study of zeolite A, sodium aluminosilicate, magnesium silicate, and aluminum hydroxide in dogs.
Cefali, EA; McConnell, WR; Nolan, JC; Walters, DL, 1995
)
0.29
"The reported geographical association between Alzheimer's disease and levels of aluminium (Al) in water supplies may reflect the inverse relation between Al and silicon (Si) concentrations in water, and the potential for Si to reduce the bioavailability of the metal."( Effect of silicon on gastrointestinal absorption of aluminium.
Barker, J; Day, JP; Edwardson, JA; Ferrier, IN; Lilley, JS; Moore, PB; Newton, GW; Templar, J, 1993
)
0.29
"The chemical affinity of silicic acid for aluminium (AI) has been shown to reduce the bioavailability of AI in studies of human gastrointestinal (GI) absorption."( The role of silicic acid in the renal excretion of aluminium.
Bellia, JP; Birchall, JD; Roberts, NB,
)
0.13
" By extrapolation from animal studies, the daily dietary intakes of these elements needed to prevent deficiency or to provide beneficial action in humans are arsenic, 12-25 micrograms; nickel, 100 micrograms; silicon, 2-5 mg (based on 10% bioavailability in natural diets) and vanadium, 10 micrograms."( Deliberations and evaluations of the approaches, endpoints and paradigms for dietary recommendations of the other trace elements.
Seaborn, CD; Uthus, EO, 1996
)
0.29
"The bioavailability of silicon in stabilized orthosilicic acid was investigated in a double blind, placebo controlled supplementation study of calves maintained on a normal diet."( Supplementation of calves with stabilized orthosilicic acid. Effect on the Si, Ca, Mg, and P concentrations in serum and the collagen concentration in skin and cartilage.
Calomme, MR; Vanden Berghe, DA, 1997
)
0.3
"Two experiments were conducted using completely randomized designs to study the bioavailability of Si from three sources to growing rats and turkeys fed semipurified diets."( Silicon bioavailability studies in young rapidly growing rats and turkeys fed semipurified diets: a comparative study.
Jia, X; Kayongo-Male, H, 1999
)
0.3
"By using (26)Al as a tracer, we investigated the effects of oligomeric and monomeric silica on the bioavailability of aluminum (study 1) and compared the availability of silicon from oligomeric and monomeric silica in the human gastrointestinal tract (study 2)."( Oligomeric but not monomeric silica prevents aluminum absorption in humans.
Day, JP; Fifield, LK; Jugdaohsingh, R; Oldham, C; Powell, JJ; Reffitt, DM; Thompson, RP, 2000
)
0.31
" The main source of silicon for humans is the diet, but the bioavailability of silicon from solid foods is not well understood."( Dietary silicon intake and absorption.
Anderson, SH; Elliott, H; Jugdaohsingh, R; Kiel, DP; Powell, JJ; Thompson, RP; Tucker, KL, 2002
)
0.31
" Beer appears to be a major contributor to Si intake, although the Si content of beer and its bioavailability in human subjects have not been well established."( The silicon content of beer and its bioavailability in healthy volunteers.
Elliott, H; Jugdaohsingh, R; Mehta, P; Powell, JJ; Shoukru, S; Sripanyakorn, S; Thompson, RP; Walker, C, 2004
)
0.32
" Appropriate agreement between three-dimensional specific absorption rate distributions measured by MR-thermography and planning calculations is achieved, if the correct position and adapted feed point parameters are considered."( Comparison of MR-thermography and planning calculations in phantoms.
Budach, V; Cho, CH; Fähling, H; Felix, R; Gellermann, J; Nadobny, J; Weihrauch, M; Weiser, M; Wlodarczyk, W; Wust, P, 2006
)
0.33
"The following competing factors have been identified as effects of zeolites on algal growth in salt water: (i) ammonia decrease: growth inhibition reduced; (ii) macro-nutrients increase, mainly silicon: stimulation of silicon-dependent algae; (iii) trace metals increase (desorption from zeolites) or decrease (adsorption): inhibition or stimulation, depending on the nature of the element and its concentration; and, (iv) changes in the chelating organics exudation: inhibition or stimulation of growth, depending on the (a) nature of the complexed element; (b) bioavailability of the complex; and (c) concentration of the elements simultaneously present in inorganic forms."( Effects of zeolites on cultures of marine micro-algae: A brief review.
Fachini, A; Vasconcelos, MT, 2006
)
0.33
" Because silicon (Si) intake can affect the bioavailability of aluminium, the object of the present study was to assess whether moderate beer consumption might, as a source of dietary Si, affect the toxicokinetics of Al and thereby limit that element's neurotoxicity."( Role of beer as a possible protective factor in preventing Alzheimer's disease.
González-Muñoz, MJ; Meseguer, I; Peña, A, 2008
)
0.35
" Increasing the bioavailability of arginine, the precursor of nitric oxide, thus potentially offers protection against end-stage disease."( Metabolic effects of a novel silicate inositol complex of the nitric oxide precursor arginine in the obese insulin-resistant JCR:LA-cp rat.
Kelly, SE; Proctor, SD; Russell, JC; Vine, DF, 2007
)
0.34
" Monomeric silicates were readily absorbed, while particulate silicates were decreasingly well absorbed with increasing polymerisation."( The comparative absorption of silicon from different foods and food supplements.
Anderson, SH; Dissayabutr, W; Jugdaohsingh, R; Powell, JJ; Sripanyakorn, S; Thompson, RP, 2009
)
0.35
" A preliminary in vivo experiment confirmed that bioavailability is not only determined by concentration, but especially by the type of food and species under which silicon is present."( Dietary silicon intake in Belgium: Sources, availability from foods, and human serum levels.
Hermans, N; Robberecht, H; Van Cauwenbergh, R; Van Vlaslaer, V, 2009
)
0.35
" Here we report controlled antibiotic activity and sustained bioavailability from SiNW arrays and also show microstructural manipulations for a tunable release rate."( Antibiofouling, sustained antibiotic release by Si nanowire templates.
Brammer, KS; Choi, C; Cobb, CJ; Connelly, LS; Jin, S; Kong, SD; Loya, M; Oh, S, 2009
)
0.35
" The results clearly demonstrate improved bioavailability of PYY3-36 via TOPSi and the importance of surface chemistry of PSi on peptide release."( Mesoporous silicon (PSi) for sustained peptide delivery: effect of psi microparticle surface chemistry on peptide YY3-36 release.
Herzig, KH; Järvinen, K; Kovalainen, M; Lehto, VP; Mäkilä, E; Mönkäre, J; Salonen, J, 2012
)
0.38
" The gastroretentive drug delivery system with a dual function presented here is a viable alternative for improving drug bioavailability in the oral route."( The mucoadhesive and gastroretentive properties of hydrophobin-coated porous silicon nanoparticle oral drug delivery systems.
Airaksinen, AJ; Bimbo, LM; Helariutta, AM; Hirvonen, JT; Laaksonen, PH; Laaksonen, TJ; Linder, MB; Mäkilä, EM; Salonen, JJ; Santos, HA; Sarparanta, MP, 2012
)
0.38
" Over the years, some studies have emerged to improve the bioavailability of this drug and of its active metabolites."( New times, new trends for ethionamide: In vitro evaluation of drug-loaded thermally carbonized porous silicon microparticles.
Gomes, P; Hirvonen, J; Mäkilä, E; Salonen, J; Santos, HA; Vale, N, 2012
)
0.38
" Electrolytically hydrided materials have the same high level magnetic properties as in high temperature gas-phase processed materials and offer an advantage of higher hydrogen absorption rate in the ferromagnetic state."( Electrolytic hydriding of LaFe(13-x)Si(x) alloys for energy efficient magnetic cooling.
Cohen, LF; Hannemann, U; Lyubina, J; Ryan, MP, 2012
)
0.38
" However, CBD-CS are preferred due to a better stability in water and improved bioavailability of siRNA on their surface."( siRNA carriers based on carbosilane dendrimers affect zeta potential and size of phospholipid vesicles.
Bryszewska, M; de la Mata, FJ; Garaiova, Z; Gomez-Ramirez, R; Hianik, T; Ionov, M; Klajnert, B; Pędziwiatr-Werbicka, E; Waczulikova, I; Wróbel, D, 2012
)
0.38
"), weathering during 32 weeks was inferred from bioavailability of magnesium (Mg) in soil and plant."( Olivine weathering in soil, and its effects on growth and nutrient uptake in Ryegrass (Lolium perenne L.): a pot experiment.
Goedhart, PW; Knops, P; Steenhuizen, JW; ten Berge, HF; van der Meer, HG; Verhagen, J, 2012
)
0.38
" Subcutaneous nanocarriers are demonstrated to be capable to sustain PYY3-36 delivery over 4 days, with the high absolute bioavailability values of PYY3-36."( Development of porous silicon nanocarriers for parenteral peptide delivery.
Herzig, KH; Järvinen, K; Kaasalainen, M; Kovalainen, M; Lehto, VP; Mönkäre, J; Riikonen, J; Salonen, J, 2013
)
0.39
"Mesoporous materials are promising candidates for improving dissolution rate of poorly water-soluble drugs in vitro and their bioavailability in vivo."( Systematic in vitro and in vivo study on porous silicon to improve the oral bioavailability of celecoxib.
Araújo, F; Correia, A; Hirvonen, J; Järvinen, K; Kovalainen, M; Lehto, VP; Lehtonen, M; Leppänen, J; Näkki, S; Rantanen, J; Riikonen, J; Santos, HA; Xu, W, 2015
)
0.42
" This study aimed to assess the bioavailability of Si from OSA stabilized by vanillin (OSA-VC)."( Digestive absorption of silicon, supplemented as orthosilicic acid-vanillin complex.
Cazaubiel, M; Croizet, K; Housez, B; Marcowycz, A; Maudet, C; Rinaldi, G, 2015
)
0.42
"Although many studies have investigated the metabolism and bioavailability of Si supplemented in foods or as a food ingredient, this was the first to investigate and demonstrate the digestibility of OSA administered in a complex form with vanillin."( Digestive absorption of silicon, supplemented as orthosilicic acid-vanillin complex.
Cazaubiel, M; Croizet, K; Housez, B; Marcowycz, A; Maudet, C; Rinaldi, G, 2015
)
0.42
" The challenge of using peptides as drugs arises from their poor bioavailability resulting from the low permeability of biological membranes and their instability."( Novel delivery systems for improving the clinical use of peptides.
Herzig, KH; Järvinen, K; Kovalainen, M; Lehto, VP; Mönkäre, J; Pesonen, U; Riikonen, J; Salonen, J; Vlasova, M, 2015
)
0.42
"The oral bioavailability of a poorly water-soluble drug is often inadequate for the desired therapeutic effect."( Controlled Dissolution of Griseofulvin Solid Dispersions from Electrosprayed Enteric Polymer Micromatrix Particles: Physicochemical Characterization and in Vitro Evaluation.
Araújo, F; Correia, A; Kaasalainen, M; Murtomaa, M; Peurla, M; Roine, J; Salonen, J; Santos, HA, 2015
)
0.42
"Plants growing on polluted soils need to control the bioavailability of pollutants to reduce their toxicity."( Microscopic biomineralization processes and Zn bioavailability: a synchrotron-based investigation of Pistacia lentiscus L. roots.
Casu, MA; De Giudici, G; Gianoncelli, A; Iadecola, A; Lattanzi, P; Medas, D; Meneghini, C; Podda, S, 2015
)
0.42
" Through this approach peptides are expected to increase their bioavailability and efficiency in vivo both by their specific release at the intestinal level and also by the reduced enzymatic activity."( Microfluidic Assembly of a Multifunctional Tailorable Composite System Designed for Site Specific Combined Oral Delivery of Peptide Drugs.
Araújo, F; Granja, PL; Herranz-Blanco, B; Hirvonen, JT; Liu, D; Mäkilä, EM; Salonen, JJ; Santos, HA; Sarmento, B; Shahbazi, MA; Shrestha, N, 2015
)
0.42
" Indeed, biochars efficiently reduce the bioavailability of organic and inorganic pollutants."( Elaboration, characteristics and advantages of biochars for the management of contaminated soils with a specific overview on Miscanthus biochars.
Deboffe, C; Douay, F; Heymans, S; Janus, A; Pelfrêne, A; Waterlot, C, 2015
)
0.42
" Bioavailability of growth-inducing and anti-thrombotic agents on the hollow fiber-blood interface inhibits thrombosis."( Nanoliposomal Growth Hormone and Sodium Nitrite Release from Silicone Fibers Reduces Thrombus Formation Under Flow.
Amoabediny, G; Banikarimi, SP; Klein-Nulend, J; Malaie-Balasi, Z; Pouran, B; Salehi-Nik, N; Zandieh-Doulabi, B, 2016
)
0.43
" Functionalization with a diblock polymer improves PSi nanoparticle colloidal stability, in vivo pharmacokinetics, and intracellular bioavailability through endosomal escape, enabling PNA to inhibit miR-122 in vivo."( Porous Silicon and Polymer Nanocomposites for Delivery of Peptide Nucleic Acids as Anti-MicroRNA Therapies.
Beavers, KR; Duvall, CL; Fain, JS; Kavanaugh, TE; Kilchrist, KV; Mares, JW; Shen, T; Vickers, KC; Weiss, SM; Werfel, TA; Wiese, CB, 2016
)
0.43
"Steel slag has been widely used as amendment and silicon fertilizer to alleviate the mobility and bioavailability of heavy metals in soil."( In situ stabilization of heavy metals in multiple-metal contaminated paddy soil using different steel slag-based silicon fertilizer.
Duan, A; Liang, Y; Liu, Z; Ning, D; Song, A, 2016
)
0.43
" The silicon bioaccessibility and bioavailability of the five leafy vegetables (biofortified or not) and of the supplement were assessed by applying a protocol consisting of in vitro gastrointestinal digestion coupled with a Caco-2 cell model."( Integrated in vitro approaches to assess the bioaccessibility and bioavailability of silicon-biofortified leafy vegetables and preliminary effects on bone.
Brunetti, G; Cardinali, A; Colucci, S; D'Imperio, M; Gigante, I; Minervini, F; Santamaria, P; Serio, F, 2017
)
0.46
" The objective of this study was to determine the effect of Si-treated calcium metallurgical slag and battery slag on the As, Se, Cd, Pb, Ni, Cr, and Hg mobility and bioavailability in mine tailings (Xikuangshan mine, Hunan, China)."( Si-based technologies for reduction of the pollutant leaching from landfills and mine tails.
Bocharnikova, E; Jiang, J; Matichenkov, V; Yuejin, C, 2017
)
0.46
"This study assessed the effectiveness of limestone-montmorillonite-rapeseed residue-Si fertilizer compound amendment on the bioavailability and crop uptake of cadmium (Cd) and enzyme activities in acidic paddy soils."( Impacts of a Compound Amendment on Cd Immobilization, Enzyme Activities and Crop Uptake in Acidic Cd-Contaminated Paddy Soils.
Cheng, W; Du, D; Fu, Z; Guo, Z; Lei, P; Shan, S; Wu, L; Wu, M; Wu, S, 2018
)
0.48
"The bioavailability of pollen bioactive compounds for humans is limited."( Bee Collected Pollen with Enhanced Health Benefits, Produced by Fermentation with a Kombucha Consortium.
Constantinescu-Aruxandei, D; Cornea, CP; Diguță, CF; Israel-Roming, F; Mănoiu, S; Matei, F; Moraru, A; Moraru, I; Oancea, A; Oancea, F; Ștefan, LM; Toma, A; Uțoiu, E; Vrăjmașu, VV, 2018
)
0.48
" In vitro bioavailability of this supplement was significantly higher than other commercial supplements tested, all of which claim available silica content."( Bioavailability of a novel form of silicon supplement.
Belton, DJ; Burton, EJ; Perry, CC; Scholey, DV, 2018
)
0.48
" However, the impact of grassland degradation on the distribution and bioavailability of soil Si is largely unknown."( Impact of grassland degradation on the distribution and bioavailability of soil silicon: Implications for the Si cycle in grasslands.
Hao, Q; Li, J; Liu, H; Song, Z; Xia, S; Yang, S; Yang, W; Yang, X; Yu, C; Zhang, X, 2019
)
0.51
" However, the clinical application of curcumin has been restricted by the poor water solubility and low bioavailability of this molecule."( Oral Curcumin via Hydrophobic Porous Silicon Carrier: Preparation, Characterization, and Toxicological Evaluation In Vivo.
Ge, Y; Li, J; Li, W; Liu, D; Wang, L; Zhang, Y; Zhao, M; Zheng, T; Zhu, X, 2019
)
0.51
" Biological incorporation of Silicon (Si) into Sp increases its bioavailability for potential food supplement applications."( Effect of spirulina and silicon-enriched spirulina on metabolic syndrome features, oxidative stress and mitochondrial activity in Zucker fatty rats.
Bonafos, B; Casas, F; Coudray, C; Feillet-Coudray, C; Fouret, G; Gaillet, S; Jouy, N; Jover, B; Vidé, J, 2019
)
0.51
" The nutritional supply and bioavailability of silicon are often inadequate."( Dietary Supplementation with Silicon-Enriched Spirulina Improves Arterial Remodeling and Function in Hypertensive Rats.
Arthur-Ataam, J; Bideaux, P; Charrabi, A; Eddahibi, S; Fromy, B; Jouy, N; Liu, K; Pasqualin, C; Richard, S; Sicard, P; Virsolvy, A, 2019
)
0.51
" Field experiments were conducted to explore the impacts of ten silicon (Si) rich amendments on Cd bioavailability and accumulation by maize and wheat irrigated with sewage effluents."( Efficiency of various silicon rich amendments on growth and cadmium accumulation in field grown cereals and health risk assessment.
Ali, S; Anayat, A; Anwar Ul Haq, M; Rizwan, M; Sohail, MI; Waris, AA; Yousaf, B; Zia Ur Rehman, M, 2020
)
0.56
" Bioavailability was investigated using a Caco2 cell line alone, or co-culturing with a HT29-MTX cell line."( In vitro evaluation of different organic matrices used to modulate silicon bioavailability.
Benetti, F; Pezzani, R; Tedesco, E, 2020
)
0.56
"The intestinal epithelial and mucus barriers on the gastrointestinal tract limit the bioavailability of oral protein or peptide drugs."( Bioinspired zwitterionic polyphosphoester modified porous silicon nanoparticles for efficient oral insulin delivery.
Bai, X; Li, Y; Liu, W; Liu, X; Rao, R; Tan, X; Yang, X; Zhou, H, 2021
)
0.62
" Both soil incubation and pot experiments were conducted to assess the effect of OSiF and MSiF on bioavailability of Cd and Pb in soil and their accumulation in rice."( Effect of organosilicone and mineral silicon fertilizers on chemical forms of cadmium and lead in soil and their accumulation in rice.
Liang, Y; Mei, Y; Peng, M; Tan, L; Xiao, Z, 2021
)
0.62
" Buparvaquone is a potential drug against the leishmaniases, but it is highly hydrophobic resulting in poor bioavailability and low therapeutic efficacy."( Biogenic nanoporous silicon carrier improves the efficacy of buparvaquone against resistant visceral leishmaniasis.
Lehto, VP; Mondal, S; Näkki, S; Närvänen, A; Nissinen, T; Rantanen, J; Riikonen, J; Thapa, R, 2021
)
0.62
" The results showed that relative to the control, all amendments significantly decreased both soil Cd bioavailability and its uptake in plant tissues, promoting healthy wheat growth and yield."( Supplying silicon alters microbial community and reduces soil cadmium bioavailability to promote health wheat growth and yield.
Bi, J; Fan, F; Jeyakumar, P; Li, Z; Song, A; Wang, E; Wang, H; Wang, S; Xu, D, 2021
)
0.62
" Different soil factors influence the Si bioavailability in soil-plant system."( Effects of silicon on heavy metal uptake at the soil-plant interphase: A review.
Ali, S; Awan, SA; Brestic, M; Hassan, MJ; Huang, L; Khan, I; Rizwan, M; Zhang, X, 2021
)
0.62
" The 3 different oral Si formulations tested, in powder and liquid presentations, provide highly bioavailable Si and present an equivalent relative absorption in healthy humans."( Relative absorption of silicon from different formulations of dietary supplements: a pilot randomized, double-blind, crossover post-prandial study.
Arola, L; Boqué, N; Pedret, A; Puiggrós, F; Solà, R; Valls, RM, 2021
)
0.62
" Exogenously applied Si and AM species enhanced soil glomalin and phosphatases activity, hence decreased metal bioavailability in soil, increased plant nutrient acquisition, biomass and chlorophylls; with maximum benefits provided by M2, closely followed by Si and least by M1."( Arbuscular mycorrhizae and silicon alleviate arsenic toxicity by enhancing soil nutrient availability, starch degradation and productivity in Cajanus cajan (L.) Millsp.
Bhalla, S; Garg, N, 2021
)
0.62
" The results showed that the co-application of water management and foliar spraying Si could effectively decrease the bioavailability of Cd and As in soil and reduce the uptake and transport of Cd and As in rice."( Co-application of water management and foliar spraying silicon to reduce cadmium and arsenic uptake in rice: A two-year field experiment.
Gu, J; Liao, B; Wei, B; Zeng, P; Zhou, H, 2022
)
0.72
" Replacing carbon with silicon in pharmaceuticals and pesticides has shown to result in positive effects on efficacy and selectivity, physicochemical properties, and bioavailability and also to eliminate or improve human or environmental safety properties as well as to provide novelty and new intellectual property in many cases."( Silicon-Containing Complex II Acaricides─Design, Synthesis, and Pharmacological Optimization.
Cheng, J; Li, Z; Maienfisch, P; Quan, X; Wang, X; Zhou, C, 2022
)
0.72
"The impacts of silicon (Si) fertilizers on cadmium (Cd) bioavailability in soil and Cd accumulation in paddy-rice plants were investigated in a field positioning test."( [Impacts of Uptake and Accumulation of Cd on Double Rice-Paddy Soil by Silicon Fertilizer Continuous Application].
Deng, K; Ji, XH; Liu, SH; Peng, H; Shi, Y; Wei, W, 2022
)
0.72
"The mechanism of silicon (Si) influencing cadmium (Cd) speciation and bioavailability in alkaline paddy soil solution remains unclear."( Solution chemistry mechanisms of exogenous silicon influencing the speciation and bioavailability of cadmium in alkaline paddy soil.
Chen, A; Guo, L; He, N; Li, C; Liu, M; Wang, Y; Yang, D, 2022
)
0.72
" The (nano)composite hydrogels synthesized displayed filler-dependent absorption properties of two cationic dyes used as model water pollutants, Laponite XLS-reinforced hydrogel demonstrating both the highest absorption rate and absorption capacity."( Adjusting Some Properties of Poly(methacrylic acid) (Nano)Composite Hydrogels by Means of Silicon-Containing Inorganic Fillers.
Alexandrescu, E; Burlacu, S; Gîfu, C; Ianchiș, R; Mihăescu, CI; Ninciuleanu, CM; Nistor, CL; Petcu, C; Preda, S; Scomoroscenco, C; Teodorescu, M; Trică, B, 2022
)
0.72
" Two seasons of continuous field experiments were conducted in heavily Cd-polluted soil to study how the co-application of LS and Si fertilizer (namely soil-applied Si and foliar-sprayed Si) influences Cd and Si bioavailability in soil and Cd uptake and transport in rice."( Co-application of combined amendment (limestone and sepiolite) and Si fertilizer reduces rice Cd uptake and transport through Cd immobilization and Si-Cd antagonism.
Gu, J; Liao, B; Liao, Y; Liu, J; Luo, X; Wei, B; Zeng, P; Zhou, H, 2023
)
0.91
" The soil application of these treatments reduced the Cd toxicity by enhancing Cd-tolerance index, decreasing bioavailability of soil Cd, reducing Cd contents and translocation in plants, improving gaseous exchange, photosynthesis, and increasing the antioxidant enzyme activities and their transcriptions."( Mitigating Cd and bacterial wilt stress in tomato plants through trico-synthesized silicon nanoparticles and Trichoderma metabolites.
Ahmad, A; Alam, SS; Ali, A; Khan, RAA; Najeeb, S; Shakoor, A; Tong, L, 2023
)
0.91
"Heavy metal pollution threatens food security, and rhizosphere acidification will increase the bioavailability of heavy metals."( Silicon-phosphorus pathway mitigates heavy metal stress by buffering rhizosphere acidification.
Liang, Y; Pang, Z; Peng, H; Wang, Y; Yin, W; Zeng, W, 2023
)
0.91

Dosage Studied

The transient effects are coupled with a decrease of intracellular silicon levels over time after exposure. PAH congeners were spiked in silicon rubber membrane (SRMs) and were then introduced into the cell medium by the passive dosing method. Daunorubicin-loaded porous silicon (pSi) particles were dosed 8 to 9 weeks before PVR induction.

ExcerptRelevanceReference
" As recommended during acute diarrhea, the dosage of Actapulgite was doubled during the first three treatment days (2 to 4 packets a day according to the patient's weight), and reduced by half thereafter."( [Therapeutic evaluation of Mormoiron attapulgite in acute diarrheas of infants and children. A multicenter study in controlled liberal practice versus placebo in 113 patients].
Charritat, JL; Corbineau, D; Guth, S; Meunier, M; Pernin, P; Pflieger, H, 1992
)
0.28
" The isotopes 99Tc, the decay product of 99Tcm, and 3H are soft beta-emitter radionuclides and the use of unsealed sources can frequently produce contamination and excessive internal dosing for workers."( Determination of low-energy beta-emitter radionuclides deposited on surfaces by attapulgite treatment.
Belfiore, A; Lo Moro, A; Panciatici, G; Raspi, G, 1990
)
0.28
" The data of this study showed that TMOS has a steep dose-response curve with no observable effects at 10 ppm, very minimal effects at 15 ppm, moderate to severe effects at 30 ppm, and severe effects and lethality at 45 ppm."( Subchronic inhalation toxicity of tetramethoxysilane in rats.
Geil, RG; Hobbs, EJ; Kolesar, GB; Malczewski, RM; Siddiqui, WH, 1989
)
0.28
" The observed changes reflect significant dose-response and agent-response relationships."( Lung changes in rats following inhalation exposure to volcanic ash for two years.
Buschbom, RL; Clark, ML; Dagle, GE; Wehner, AP, 1986
)
0.27
"Alpha radiation dosage is an important occupational health factor in the mining of uranium and mineral sands."( Alpha radiation detection using silicon memory chips--preliminary studies.
Haskard, M; Pace, R; Paix, D, 1993
)
0.29
" To address this issue a cohort analysis of dose-response relations for crystalline silica and lung cancer mortality was conducted among diatomaceous earth workers classified according to the presence or absence of radiological silicosis."( Crystalline silica exposure, radiological silicosis, and lung cancer mortality in diatomaceous earth industry workers.
Checkoway, H; Demers, PA; Hughes, JM; Seixas, NS; Weill, H, 1999
)
0.3
"The dose-response relation observed between cumulative exposure to respirable crystalline silica and lung cancer mortality among workers without radiological silicosis suggests that silicosis is not a necessary co-condition for silica related lung carcinogenesis."( Crystalline silica exposure, radiological silicosis, and lung cancer mortality in diatomaceous earth industry workers.
Checkoway, H; Demers, PA; Hughes, JM; Seixas, NS; Weill, H, 1999
)
0.3
" The washout period between each dosage applied was at least 12 days."( Antiplatelet and anticoagulant effects of "HN-11 500," a selective thromboxane receptor antagonist.
Breddin, HK; Fellier, H; Radziwon, P; Schenk, JF, 2001
)
0.31
"The purpose of this study was to investigate the dose-response characteristics, including ghosting effects, of an amorphous silicon-based electronic portal imaging device (a-Si EPID) under clinical conditions."( Dose-response and ghosting effects of an amorphous silicon electronic portal imaging device.
Louwe, RJ; McDermott, LN; Mijnheer, BJ; Sonke, JJ; van Herk, MB, 2004
)
0.32
" This leads to huge gains in sensitivity and, consequently, a reduction in the radiation dosage that needs to be administered to the patient."( Optimizing Compton camera geometries.
Chelikani, S; Gore, J; Zubal, G, 2004
)
0.32
" The interconnects suppress Fick diffusion of both charged and uncharged species, so that they can be utilized as ionic gates with complete external control over the transport rates of anionic and cationic species, thus realizing the possibility for implementation of these Si-compatible oxide interconnects in microchip analyses for use as dosing valves or sensors."( Si-supported mesoporous and microporous oxide interconnects as electrophoretic gates for application in microfluidic devices.
Blank, DH; Chowdhury, SR; Nijdam, W; Schmuhl, R; Sekulić, J; ten Elshof, JE; van den Berg, A; van Rijn, CJ, 2005
)
0.33
" This method is accurate and quick with less reagent dosage and broa linear range."( [Studies on the determination of silicon and phosphorus in ferromanganese by ICP-AES].
Mo, QJ; Song, LH; Wang, XY, 2004
)
0.32
" A prerequisite for any clinical dosimetric application is a detailed understanding of the detector's dose-response behavior."( Dose-response characteristics of an amorphous silicon EPID.
Georg, D; Hefner, A; Winkler, P, 2005
)
0.33
" In the present study, the dose-response characteristics of 11 iViewGT EPIDs were investigated with respect to dose rate, total dose and field size."( An intercomparison of 11 amorphous silicon EPIDs of the same type: implications for portal dosimetry.
Georg, D; Winkler, P, 2006
)
0.33
"1 ion channel blocker (TEA) dosage response is characterized and the binding activity is examined."( Open-access microfluidic patch-clamp array with raised lateral cell trapping sites.
Hung, PJ; Lau, AY; Lee, LP; Wu, AR, 2006
)
0.33
" It is shown how this can reduce the dosage time from hours to seconds over previous diffusion based approaches, using as little as 20 mJ of energy per dose."( Electrokinetic microfluidic devices for rapid, low power drug delivery in autonomous microsystems.
Chung, AJ; Erickson, D; Kim, D, 2008
)
0.35
" Whereas Pc 4-PDT photodamages Bcl-2 and Bcl-xL, Pc 181-PDT causes much less photodamage to Bcl-2 over the same dose-response range relative to cell killing, with earlier cleavage of Bid and slower caspase-3-dependent apoptosis."( Structural factors and mechanisms underlying the improved photodynamic cell killing with silicon phthalocyanine photosensitizers directed to lysosomes versus mitochondria.
Azizuddin, K; Berlin, JC; Chiu, SM; Delos Santos, GB; Kenney, ME; Lam, M; Nieminen, AL; Oleinick, NL; Peng, X; Rodriguez, ME; Wu, H; Xue, LY; Zhang, P,
)
0.13
" High fitness and adaptation of diatoms to various Si levels in marine environments might arise in part by global regulations from gene (expression level) to genomic (organization in clusters, dosage compensation by gene duplication), and by post-transcriptional regulation and spatial distribution of SIT proteins."( Genome-wide transcriptome analyses of silicon metabolism in Phaeodactylum tricornutum reveal the multilevel regulation of silicic acid transporters.
Heijde, M; Jourdren, L; Le Crom, S; Lopez, PJ; Luo, G; Quinet, M; Sapriel, G; Tanty, V, 2009
)
0.35
" Such mixing conditions often lead to large niosomes with high polydispersity in size and thus affect the consistency of niosome dosage or imaging quality."( Controlled self-assembly of monodisperse niosomes by microfluidic hydrodynamic focusing.
Jahn, A; Lo, CT; Locascio, LE; Vreeland, WN, 2010
)
0.36
"5 mm thickness were made from a polyester resin-salt mixture and dosed with equal arsenic and selenium concentrations ranging from 0 to 30 microg g(-1)."( Simultaneous assessment of arsenic and selenium in human nail phantoms using a portable x-ray tube and a detector.
Fleming, DE; Gherase, MR; Roy, CW, 2010
)
0.36
" The influence of alkaline activator dosage and Si/Al molar ratio on the compressive strength and microstructure of MSWI fly ash-based geopolymer was investigated."( The effects of alkaline dosage and Si/Al ratio on the immobilization of heavy metals in municipal solid waste incineration fly ash-based geopolymer.
Shi, Y; Wang, W; Zheng, L, 2010
)
0.36
" Given the critical importance of the dose-response relationship, we present the use of quartz crystal microgravimetry (QCM) to accurately measure nanoparticle concentration in a colloidal suspension."( Measurement of nanoparticle concentration using quartz crystal microgravimetry.
Choi, J; Purdum, G; Reipa, V, 2010
)
0.36
" Using model DNA and protein dose-response assays, the number of cross-platform data sets exhibiting high correlation (>0."( Increased cross-platform microarray data set correlation via substrate-independent nanofilms.
Spillman, SD, 2011
)
0.37
" The results of sorghum pot growth in both red and crimson acidic soil for 30 days indicated that adding the MFGDR at a dosage of 2 g kg(-1) in total soil weight would increase the growth rate of biomass by 24."( Preparation of a modified flue gas desulphurization residue and its effect on pot sorghum growth and acidic soil amelioration.
Li, Y; Shi, L; Tang, S; Xie, K; Xu, P, 2011
)
0.37
" A major advantage of HaloChip is the ability to increase throughout by spatially encoding multiple dosing conditions on the same chip."( Single cell DNA damage/repair assay using HaloChip.
Ma, L; Qiao, Y; Su, M; Wang, C, 2012
)
0.38
"The number of active pharmaceutical substances having high therapeutic potential but low water solubility is constantly increasing, making it difficult to formulate these compounds as oral dosage forms."( Emerging trends in the stabilization of amorphous drugs.
Grohganz, H; Laitinen, R; Löbmann, K; Rades, T; Strachan, CJ, 2013
)
0.39
" These data show that nanocapsulated quercetin possesses the potential bioactivity to reduce the drug dosage frequency, as well as increase patient compliance."( Co-encapsulation of biodegradable nanoparticles with silicon quantum dots and quercetin for monitored delivery.
Ahire, J; Bao, Y; Chao, Y; Wang, Q, 2013
)
0.39
" In addition, weekly dosing of PCPS/STAT3 siRNA for four weeks did not cause signs of subacute toxicity based on changes in body weight, hematology, blood chemistry, and major organ histology."( High capacity nanoporous silicon carrier for systemic delivery of gene silencing therapeutics.
Ferrari, M; Gu, J; Guo, X; Kim, HC; Liu, X; Mai, J; Mao, ZW; Mu, C; Qin, G; Shen, H; Shen, J; Wolfram, J; Xia, X; Xu, R; Yang, Y, 2013
)
0.39
" Such enhancement in accumulation could be leveraged to increase therapeutic efficacy and reduce drug dosing in cancer therapy."( Transient mild hyperthermia induces E-selectin mediated localization of mesoporous silicon vectors in solid tumors.
Ferrari, M; Kirui, DK; Liu, X; Mai, J; Palange, AL; Qin, G; Shen, H; van de Ven, AL, 2014
)
0.4
" The increase in VEGF concentrations during operations offers useful insight into dosage timing during cancer therapy."( Magnetic-composite-modified polycrystalline silicon nanowire field-effect transistor for vascular endothelial growth factor detection and cancer diagnosis.
Chen, HC; Chen, MC; Ho, CH; Hua, MY; Huang, CC; Lai, CS; Lin, CC; Lin, CY; Liu, YC; Qiu, JT; Tsai, RY; Tu, YM; Wu, TS; Xiao, MC; Yang, FL; Yang, HW, 2014
)
0.4
" This study evaluated the efficacy of the silicone-based surface film, Aquatain® Mosquito Formulation (AMF), for the control of the Afrotropical malaria vectors, Anopheles gambiae sensu stricto and Anopheles arabiensis in laboratory dose-response assays and standardized field tests."( Aquatain® Mosquito Formulation (AMF) for the control of immature Anopheles gambiae sensu stricto and Anopheles arabiensis: dose-responses, persistence and sub-lethal effects.
Fillinger, U; Lindsay, SW; Mbare, O, 2014
)
0.4
" After the silver NCs were modified by an antibody and employed in immunoassay with silicon nanowire arrays as the substrate, the antigen concentration-dependent SERS spectra and dose-response calibration curves were obtained."( Silver nanocube-mediated sensitive immunoassay based on surface-enhanced Raman scattering assisted by etched silicon nanowire arrays.
Jiang, T; Zhang, L; Zhou, J, 2014
)
0.4
" The effects of various reaction parameters such as H2O2 dosage, temperature, initial pH value, Fe–Si–B dosage and initial RhB concentration on the degradation of RhB were studied."( Efficient degradation of rhodamine B using Fe-based metallic glass catalyst by Fenton-like process.
Pan, Y; Wang, X; Wu, J; Zhu, Z, 2014
)
0.4
" Daunorubicin-loaded porous silicon (pSi) particles were dosed 8 to 9 weeks before PVR induction, and PVR severity score was dose dependent (Spearman ρ = -0."( A Novel Approach of Daunorubicin Application on Formation of Proliferative Retinopathy Using a Porous Silicon Controlled Delivery System: Pharmacodynamics.
Cheng, L; Freeman, WR; Hou, H; Huffman, K; Rios, S; Sailor, MJ, 2015
)
0.42
" This route is cost-effective and suitable for self-administration, and the development of appropriate dosing equipment has made performing the repeated injections relatively easy; however, only few clinical subcutaneous peptide delivery systems provide sustained peptide release."( Novel delivery systems for improving the clinical use of peptides.
Herzig, KH; Järvinen, K; Kovalainen, M; Lehto, VP; Mönkäre, J; Pesonen, U; Riikonen, J; Salonen, J; Vlasova, M, 2015
)
0.42
" These ETH-conjugated NPs have great potential in reducing dosing frequency of ETH in the treatment of multidrug-resistant tuberculosis (MDR-TB)."( Preparation and biological evaluation of ethionamide-mesoporous silicon nanoparticles against Mycobacterium tuberculosis.
Correia, A; Figueiredo, P; Fraga, A; Hirvonen, J; Mäkilä, E; Pedrosa, J; Salonen, J; Santos, HA; Silva, S; Vale, N, 2017
)
0.46
" The aim of this study was to investigate the dose-response characteristics of the EPID in the Unity MR-linac (Elekta AB, Stockholm, Sweden) relevant for dosimetric applications under clinical conditions."( Characterization of the a-Si EPID in the unity MR-linac for dosimetric applications.
Baldvinsson, G; Mans, A; Mijnheer, BJ; Olaciregui-Ruiz, I; Torres-Xirau, I; van der Heide, UA, 2018
)
0.48
" Plants dosed with 5 μM DMA grew well vegetatively but exhibited straighthead disorder at the lowest Si dose, and this DMA-induced yield loss reversed with increasing solution Si."( Silicon Decreases Dimethylarsinic Acid Concentration in Rice Grain and Mitigates Straighthead Disorder.
Dykes, GE; Limmer, MA; Seyfferth, AL; Wise, P, 2018
)
0.48
"4% the dosage was not stated."( Botulinum Toxin A Plays an Important Role in the Placement of Implants Deep Within the Pectoralis Major Muscle for Mammaplasty: A Systematic Review and Meta-analysis.
Li, T; Liu, Y; Zhang, W, 2018
)
0.48
" Surface morphology, elemental composition, crystal structure and surface area of "salt-based biochars" were analyzed by SEM + EDS, XRD, FTIR and BET, and the effects of the dosage of absorbent and pH of solution on the adsorption process were explored."( Modification of biochar with silicon by one-step sintering and understanding of adsorption mechanism on copper ions.
Bao, Y; Cheng, W; Liu, J; Yang, X, 2020
)
0.56
" to adapt dosage or predict response."( Luminescent silicon nanoparticles for distinctive tracking of cellular targeting and trafficking.
Beck, S; Cheon, J; Jin, Y; Joo, J; Kang, MH; Kim, GH; Kim, M; Lee, G; Sung, J, 2020
)
0.56
" However, ocular dosage forms like eye drop solution affect the routine life style of patients due to frequent dosing schedule."( Hyaluronic acid and graphene oxide loaded silicon contact lens for corneal epithelial healing.
Huang, C; Li, Y; Yang, X; Zhang, X, 2021
)
0.62
" Due to the limitation of the dosage form of the drug and the special environment of the gastrointestinal tract, traditional oral drugs have the disadvantage of not being able to make the drug effective in specific lesions when treating inflammatory bowel disease."( Effect of Porous Silicon Nanoparticle Drug-Loading System on Ulcerative Colitis.
Cheng, Q; Wang, J; Zhang, M, 2021
)
0.62
"3 nM, which is four orders of magnitude lower than an infectious dosage of anthrax spores for human beings (60 μM)."( Dual-emission of silicon nanoparticles encapsulated lanthanide-based metal-organic frameworks for ratiometric fluorescence detection of bacterial spores.
Cui, Z; Guo, R; Li, H; Li, M; Mei, S; Qiu, Y; Wang, L; Wei, C; Wei, X; Wen, Z; Xie, F; Yang, B; Yang, D; Zhang, W, 2020
)
0.56
"67%)) in a dose-response study."( Toxicity and tissue accumulation characteristics of the herbicide pendimethalin under silicon application in ginger (Zingiber officinale Roscoe).
Kong, Y; Li, Y; Lv, Y; Wang, K; Xu, K, 2022
)
0.72
" PAH congeners were spiked in silicon rubber membrane (SRMs) and were then introduced into the cell medium by the passive dosing method to reach a freely dissolved concentration for BeWo cell exposure."( Effects of polycyclic aromatic hydrocarbons on gestational hormone production in a placental cell line: Application of passive dosing to in vitro tests.
Alzate B, V; García L, JJ; Gil, VC; Molina P, FJ; Noreña, E; Porras, J; Quintana-Castillo, JC; Ramos-Contreras, C; Sanchez, JB; Tavera, EA; Valderrama, JFN, 2022
)
0.72
" By using silicon dosage in cells, we showed that the transient effects are coupled with a decrease of intracellular silicon levels over time after exposure."( About the Transient Effects of Synthetic Amorphous Silica: An In Vitro Study on Macrophages.
Collin-Faure, V; Fenel, D; Rabilloud, T; Sergent, JA; Torres, A, 2022
)
0.72
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Occurs in Manufacturing (37 Product(s))

Product Categories

Product CategoryProducts
Vitamins & Supplements28
Beauty & Personal Care3
Professional Supplements5
Active Lifestyle & Fitness1

Products

ProductBrandCategoryCompounds Matched from IngredientsDate Retrieved
Aurora NutraScience Ultra Liposomal Biotin+ -- 10000 mcg - 10 fl ozAurora NutraScienceVitamins & SupplementsVitamin C, Biotin, Vitamin D3, Methylsulfonylmethane, Vitamin B5, Vitamin B6, Vitamin A, Silicon, Vitamin B12, Vitamin B62024-11-29 10:47:42
BioSil Advanced Collagen Generator - Beauty Bones Joints -- 0.5 fl ozBioSilVitamins & SupplementsCholine, Silicon2024-11-29 10:47:42
BioSil Advanced Collagen Generator - Beauty Bones Joints -- 1 fl ozBioSilVitamins & SupplementsCholine, Silicon2024-11-29 10:47:42
BioSil Advanced Collagen Generator - Hair Skin Nails -- 30 Vegan CapsulesBioSilVitamins & SupplementsCholine, Silicon2024-11-29 10:47:42
BioSil Advanced Collagen Generator - Hair Skin Nails -- 60 Vegan CapsulesBioSilVitamins & SupplementsCholine, Silicon2024-11-29 10:47:42
BioSil Advanced Collagen Generator -- 5 mg - 60 Small Vegan Liquid CapsulesBioSilVitamins & SupplementsCholine, Silicon2024-11-29 10:47:42
BioSil Bone Collagenizer Ultra -- 60 Vegetarian CapsulesBioSilVitamins & SupplementsCholine, Inositol, Vitamin K2, Vitamin K2, Silicon, Vitamin B122024-11-29 10:47:42
BioSil Collagen Generator -- 120 Vegan CapsulesBioSilVitamins & SupplementsCholine, Silicon2024-11-29 10:47:42
BioSil Collagen Generator Advanced Hair + Nail Care with Biotin -- 60 Original CapsulesBioSilVitamins & SupplementsBiotin, Choline, Silicon2024-11-29 10:47:42
BioSil Collagen Generator Advanced Hair Care With Biotin -- 30 CapsulesBioSilVitamins & SupplementsBiotin, Choline, Silicon2024-11-29 10:47:42
BioSil Collagen Generator Plus With Vitamin C -- 30 CapsulesBioSilVitamins & SupplementsVitamin C, Choline, Silicon2024-11-29 10:47:42
BioSil Collagen Generator Plus With Vitamin C -- 60 CapsulesBioSilVitamins & SupplementsVitamin C, Choline, Silicon2024-11-29 10:47:42
BioSil Healthy Aging Collagen Generator with Selenium -- 30 CapsulesBioSilVitamins & SupplementsCholine, Selenium, Silicon2024-11-29 10:47:42
BioSil Healthy Aging Collagen Generator with Selenium -- 60 Original CapsulesBioSilVitamins & SupplementsCholine, Selenium, Silicon2024-11-29 10:47:42
BioSil On Your Game Joint Relief For Men -- 60 Vegetarian CapsulesBioSilVitamins & SupplementsCholine, Silicon2024-11-29 10:47:42
Cora Organic Cotton Overnight Pads Extra Long Super Absorbency -- 28 PadsCoraBeauty & Personal Caresilicone2024-11-29 10:47:42
Cora Ultra Thin Regular Pads -- 32 PadsCoraBeauty & Personal Caresilicone2024-11-29 10:47:42
DaVinci Laboratories Spectra Man Multi -- 120 TabletsDaVinci LaboratoriesProfessional Supplements Lipase, Octacosanol, PABA, Vitamin C, L-Aspartic Acid, Betaine HCl, Biotin, Boron, Vitamin D3, Choline, Chromium, L-Cysteine, Vitamin E, Folic Acid, Gamma Linolenic Acid, Vitamin E, L-Glutamine, Hesperidin, Inositol, Iodine, Lycopene, Manganese, Molybdenum, Niacin, PABA, Pantothenic Acid, Vitamin B6, Vitamin A, Riboflavin, Rutin, Selenium, Silicon, Thiamin, Alpha-Lipoic Acid, Vanadium, Vitamin B12, Vitamin B6, Vitamin K12024-11-29 10:47:42
DaVinci Laboratories Spectra™ Multivitamins for Adults -- 240 TabletsDaVinci LaboratoriesProfessional Supplements Lipase, Octacosanol, PABA, Vitamin C, L-Aspartic Acid, Betaine HCl, Biotin, Boron, Vitamin D3, Choline, Chromium, L-Cysteine, Vitamin E, Folic Acid, Vitamin E, L-Glutamine, Hesperidin, Inositol, Iodine, Linoleic Acid, Manganese, Molybdenum, Niacin, Nickel, PABA, Pantothenic Acid, Vitamin B6, Vitamin A, Riboflavin, Rutin, Selenium, Silicon, Thiamin, Vanadium, Vitamin B12, Vitamin B6, Vitamin K12024-11-29 10:47:42
DaVinci Laboratories Spectra™ Senior Multi -- 180 TabletsDaVinci LaboratoriesProfessional Supplements lipase, Octacosanol, PABA, Vitamin C, L-Aspartic Acid, Betaine HCl, Biotin, Boron, Vitamin D3, Choline, Chromium, Coenzyme Q10, L-Cysteine, Vitamin E, Folic Acid, Gamma Linolenic Acid, Vitamin E, Glutamic Acid, Hesperidin, Inositol, Iodine, Lutein, Lycopene, Manganese, Molybdenum, Niacin, PABA, Pantothenic Acid, Vitamin B6, Vitamin A, Riboflavin, Rutin, Selenium, Silicon, Thiamin, Alpha-Lipoic Acid, Vanadium, Vitamin B12, Vitamin B6, Vitamin K12024-11-29 10:47:42
DaVinci Laboratories Spectra™ Woman -- 120 TabletsDaVinci LaboratoriesProfessional Supplements lipase, Octacosanol, PABA, Vitamin C, L-Aspartic Acid, Biotin, Boron, Vitamin D3, Choline, Chromium, L-Cysteine, Vitamin E, Folic Acid, Gamma Linolenic Acid, Vitamin E, L-Glutamine, Hesperidin, Inositol, Iodine, Manganese, Molybdenum, Niacin, Nickel, PABA, Pantothenic Acid, Vitamin B6, Vitamin A, Riboflavin, Rutin, Selenium, Silicon, Thiamin, Vanadium, Vitamin B12, Vitamin B6, Vitamin K12024-11-29 10:47:42
DaVinci Laboratories Ultimate Prenatal Multi -- 150 TabletsDaVinci LaboratoriesProfessional Supplements lipase, Octacosanol, PABA, Vitamin C, L-Aspartic Acid, Betaine HCl, Biotin, Boron, Vitamin D3, Choline, Chromium, L-Cysteine, Vitamin E, Folic Acid, Vitamin E, L-Glutamine, Hesperidin, Inositol, Iodine, Linoleic Acid, Manganese, Molybdenum, Niacin, PABA, Pantothenic Acid, Vitamin B6, Vitamin A, Riboflavin, Rutin, Selenium, Silicon, Thiamin, Vitamin B12, Vitamin B6, Vitamin K12024-11-29 10:47:42
Emerald Labs Collagen Health for Hair Skin & Nails -- 90 Vegetable CapsulesEmerald LabsVitamins & SupplementsSilicon2024-11-29 10:47:42
Green Foods True Vitality Plant Protein Shake with DHA Vanilla -- 25.2 ozGreen FoodsActive Lifestyle & FitnessVitamin C, Biotin, Boron, Chromium, Vitamin E, Folate, Vitamin E, Iodine, Manganese, Molybdenum, Nickel, Pantothenic Acid, Vitamin B6, Vitamin A, Riboflavin, Selenium, Silicon, Thiamin, Vanadium, Vitamin B12, Vitamin B62024-11-29 10:47:42
Heaven Sent Wellgenix Balanced Essentials + Plus Liquid Vitamins Berry -- 32 fl ozHeaven SentVitamins & Supplementscitric acid, Antimony, Arginine, Vitamin C, Aspartic Acid, Kelp, Barium, Beryllium, Biotin, Bismuth, Boron, Bromide, Omega 3, Cerium, Cesium, Chromium, citric acid, Cobalt, Cystine, Vitamin E, fructose, Dysprosium, Erbium, Europium, Fluoride, Folate, Gadolinium, Gallium, Vitamin E, Glycine, Gold, Hafnium, Histidine, Holmium, Inositol, Iodine, Iodine, Isoleucine, Lanthanum, Leucine, Calcium Carbonate, Lithium, Lutetium, Lysine, Manganese, Methionine, Molybdenum, Neodymium, Niacin, Nickel, Niobium, Pantothenic Acid, Phenylalanine, Phosphorus, Praseodymium, Proline, Vitamin B6, Vitamin A, Rhenium, Riboflavin, Rubidium, Samarium, Scandium, Selenium, Serine, Silicon, Silver, Strontium, Tantalum, Tellurium, Terbium, Thallium, Thiamin, Thorium, Threonine, Thulium, Tin, Titanium, Tryptophan, Tungsten, Tyrosine, Valine, Vanadium, Vitamin B12, Vitamin B6, Vitamin K, Ytterbium, Yttrium, Zirconium2024-11-29 10:47:42
Kaged Mindset + Caffeine Nootropic Powder - Informed Sport Certified Orange Mango -- 4.13 ozKagedVitamins & Supplements Citric acid, Antimony, Vitamin C, Barium, beta-carotene, Boron, Caffeine, Chromium, Citric acid, Cobalt, Iodine, Lanthanum, Lithium, malic acid, Manganese, Molybdenum, Niacin, L-Phenylalanine, Phosphorus, Platinum, Vitamin B6, Rubidium, Silicon, Silver, Sulfur, sucralose, Vanadium, Vitamin B12, Vitamin B6, Zirconium2024-11-29 10:47:42
Kaged Mindset Nootropic Powder Orange Mango -- 3.97 ozKagedVitamins & Supplements Citric acid, Antimony, Vitamin C, Barium, beta-carotene, Boron, Chromium, Citric acid, Cobalt, Iodine, Lanthanum, Lithium, malic acid, Manganese, Molybdenum, Neodymium, Niacin, L-Phenylalanine, Phosphorus, Platinum, Vitamin B6, Rubidium, Silicon, Silver, Sulfur, sucralose, Vanadium, Vitamin B12, Vitamin B6, Zirconium2024-11-29 10:47:42
Oi Organic Initiative Organic Cotton Ultrathin Pads with Wings Super -- 10 PadsOi Organic InitiativeBeauty & Personal Caresilicone2024-11-29 10:47:42
Solgar Skin Nails & Hair -- 120 TabletsSolgarVitamins & SupplementsVitamin C, Microcrystalline cellulose, L-Lysine, Silicon2024-11-29 10:47:42
Solgar Skin Nails and Hair -- 60 TabletsSolgarVitamins & SupplementsVitamin C, Microcrystalline cellulose, L-Lysine, Silicon2024-11-29 10:47:42
SUKU Vitamins Luscious Hair -- 50 GummiesSUKU VitaminsVitamins & Supplementscitric acid, Vitamin C, Biotin, citric acid, Vitamin E, Folate, Vitamin E, Silicon, sodium citrate2024-11-29 10:47:42
Trace Minerals Research ConcenTrace® Mineral Drops, Flip Top Cap -- 4 fl ozTrace Minerals ResearchVitamins & SupplementsBoron, Chloride, chromium, iodide, Lithium, manganese, molybdenum, phosphorus, selenium, silicon2024-11-29 10:47:42
Trace Minerals Research ConcenTrace® Trace Mineral Drops -- 2 fl ozTrace Minerals ResearchVitamins & SupplementsBoron, Chloride, chromium, iodine, Lithium, manganese, molybdenum, phosphorus, selenium, silicon2024-11-29 10:47:42
Vibrant Health Maximum Vibrance Chocolate -- 28.2 ozVibrant HealthVitamins & SupplementsLipase, Policosanol, Larch Arabinogalactan, Vitamin C, Astaxanthin, Biotin, Cellulase, Vitamin D3, Chromium, Vitamin E, Vitamin B9, Vitamin E, Iodine, Lycopene, L-Lysine, Manganese, Vitamin B3, Vitamin B5, Phosphorus, Vitamin B6, Vitamin A, Vitamin B2, Selenium, Silicon, Vitamin B1, L-Valine, Vitamin B12, Vitamin B6, Vitamin K2024-11-29 10:47:42
Vibrant Health Maximum Vibrance™ Multi-Supplement Powder Vanilla Bean -- 20.74 ozVibrant HealthVitamins & SupplementsLipase, Vitamin C, Biotin, Cellulase, Vitamin D3, Chromium, Vitamin E, Folic Acid, Vitamin E, Iodine, Manganese, Mustard, Nicotinic Acid, Pantothenic Acid, Phosphorus, Pyridoxine, Vitamin A, Riboflavin, Selenium, Silicon, Thiamin, Vitamin K2024-11-29 10:47:42
Viteyes Classic Areds 2 Companion Multivitamin -- 30 CapletsViteyesVitamins & SupplementsBiotin, Boron, Chloride, Chromium, Folate, Microcrystalline cellulose, Iodine, Lycopene, Manganese, Molybdenum, Niacin, Nickel, Pantothenic Acid, Phosphorus, Vitamin B6, Vitamin A, Riboflavin, Selenium, Silicon, stearic acid, Thiamin, Vanadium, Vitamin B12, Vitamin B6, Vitamin K2024-11-29 10:47:42
Viteyes Classic AREDS 2 Companion Multivitamin Beta-Carotene Free -- 90 CapletsViteyesVitamins & SupplementsBiotin, Boron, Chloride, Chromium, Folate, Microcrystalline cellulose, Iodine, Lycopene, Molybdenum, Niacin, Nickel, Pantothenic Acid, Phosphorus, Vitamin B6, Riboflavin, Silicon, stearic acid, Thiamin, Vanadium, Vitamin B12, Vitamin B6, Vitamin K2024-11-29 10:47:42

Drug Classes (3)

ClassDescription
carbon group element atom
nonmetal atom
metalloid atomAn atom of an element that exhibits properties that are between those of metals and nonmetals, or that has a mixture of them. The term generally includes boron, silicon, germanium, arsenic, antimony, and tellurium, while carbon, aluminium, selenium, polonium, and astatine are less commonly included.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (13,091)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901787 (13.65)18.7374
1990's683 (5.22)18.2507
2000's3199 (24.44)29.6817
2010's5790 (44.23)24.3611
2020's1632 (12.47)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials71 (0.53%)5.53%
Reviews575 (4.27%)6.00%
Case Studies118 (0.88%)4.05%
Observational3 (0.02%)0.25%
Other12,694 (94.30%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (33)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Randomized Controlled Trial: Prevention of Preterm Birth Using Cervical Pessary in Pregnant Women With Short Cervix in Twins [NCT01242410]Phase 4137 participants (Actual)Interventional2011-01-31Completed
Additive Effects of Dental Bite Pads During Gymnastic Exercises for the Relief of Chronic Non-specific Neck Pain in Working Women and Men at a VDU Workplace [NCT05302466]52 participants (Actual)Interventional2021-12-01Completed
A Prospective, Open, Non-controlled Proof-of-concept Investigation to Evaluate the Function of a New Silicon Cover Film and an On-top Suction Device to be Used in a NPWT System in the Treatment of Acute and Chronic Wounds [NCT01286857]Phase 2/Phase 315 participants (Anticipated)Interventional2010-09-30Completed
Probiotics for Quality of Life in Autism Spectrum Disorders [NCT02903030]Early Phase 113 participants (Actual)Interventional2016-08-31Completed
A Randomized Open, Controlled Pilot Investigation Comparing Trauma to the Periwound Skin and Pain During Treatment With Avance NPWT System When Using Two Different Fixations [NCT02904200]2 participants (Actual)Interventional2016-10-31Terminated
A New Method of Sublingual Tonometry to Assess Tissue Perfusion in Patients With COPD and Healthy Individuals [NCT01169506]66 participants (Actual)Interventional2009-08-31Completed
Clinical Data Collection On Advanced CT System [NCT05835284]120 participants (Anticipated)Interventional2024-04-30Not yet recruiting
3D Ear Scanner-Workflow Timing and Preferences Compared to Traditional Silicone Earmold Impressions [NCT05000047]30 participants (Actual)Observational2021-05-17Completed
The Effect of Using Vaccine Reminder and Tracker Bracelets to Improve Routine Childhood Immunization Coverage and Timeliness in Pakistan: a Randomized Control Trial. [NCT03310762]1,445 participants (Actual)Interventional2017-07-19Completed
The Use of Nasal Airway Stent (Nastent®) in Patients With Sleep-disordered Breathing (SDB) Including Snoring and/or Obstructive Sleep Apnea (OSA). [NCT04305964]4 participants (Actual)Interventional2020-05-01Active, not recruiting
Double Blind,Randomized, Controlled Trial on Impact of Oral Probiotic Blend ( Lactobacillus Rhamnosus GG, L. Crispatus LBV88, L. Rhamnosus LBV96, L.Jensenii LBV116 and L. Gasseri LBV150 ) on Pregnancy Outcome [NCT04009889]170 participants (Actual)Interventional2018-04-05Completed
The Efficacy of a Toothpaste to Reduce Sensitivity [NCT00763269]Phase 3626 participants (Actual)Interventional2008-09-30Completed
Comparative, Open, Randomized Trial Between Two Silicon-based Products to Treat Postoperative Scars [NCT02584010]0 participants (Actual)Interventional2016-01-31Withdrawn
Evaluation Of Pessaries In Twin Pregnancies With A Short Cervix (25 mm) Between 20-28 WG [NCT00502190]Phase 3220 participants (Actual)Interventional2007-06-30Completed
A Prospective Pilot Study of Surgical Radiation Shielding With Vitrectomy & Silicone Oil Tamponade for the Protection of Radiation-induced Ocular Injury in the Treatment of Choroidal Melanoma With Radioactive Iodine-125 Plaque Brachytherapy [NCT01460810]20 participants (Actual)Interventional2011-07-31Completed
Effects on Coordination of Sucking, Swallowing and Breathing Process of a Valved Feeding System in Late-preterm Newborns. The Safe Oral Feeding Trial (SOFT) [NCT04400175]40 participants (Actual)Interventional2020-12-01Completed
A Comparison Between Bandage Contact Lens, Punctal Plugs and Standard Measures in Preventing Corneal Injuries Related to Exposure in Patients Admitted to the General Intensive Care Unit. [NCT01961193]105 participants (Anticipated)Interventional2015-05-31Not yet recruiting
A Randomised Trial for the Treatment of Cardiac AMyloid Light-chain Amyloidosis With the Green Tea Compound Epigallocatechin-3-gallate (TAME-AL) [NCT02015312]Phase 238 participants (Actual)Interventional2013-04-30Completed
An Open-Label, Single-Arm, Baseline-Controlled, Multicenter Study to Explore the Safety, Tolerability, Pharmacokinetics, and Efficacy of ABT-SLV187 in Subjects With Advanced Parkinson's Disease [NCT01479127]Phase 28 participants (Actual)Interventional2011-10-31Completed
Phase I Clinical Trial Using Topical Silicon Phthalocyanine (Pc 4) Photodynamic Therapy (PDT) for the Treatment of Pre-Malignant and Malignant Skin Conditions [NCT00103246]Phase 143 participants (Actual)Interventional2004-09-30Completed
Prevention of Preterm Birth Using Cervical Pessary in Pregnant Women After Threatened Preterm Labor [NCT01242384]Phase 4500 participants (Actual)Interventional2008-06-30Completed
Source and Prevention of Urinary Contamination of Vaginal Tampons During 18F-2-fluoro-2-deoxy-D-glucose (FDG) Positron Emission Tomography (PET) Examinations [NCT01215318]44 participants (Actual)Interventional2010-02-02Completed
Phase I Trial of PC 4-PDT (NSC 676418) for Cutaneous Malignancies [NCT00023790]Phase 13 participants (Actual)Interventional2001-08-31Terminated(stopped due to slow accrual)
The Effect of Subdural Drain Placement After Burr Hole Evacuation of Chronic Subdural Haematomas on Recurrence: a Prospective Randomised-controlled Multi-centre Study [NCT01785797]Phase 3260 participants (Anticipated)Interventional2013-06-30Not yet recruiting
PEEK Versus Silicon Interspinous Spacer for Reduction of Supradjacent Segment Degeneration Following Decompression and Short-Segment Instrumentation for Degenerative Lumbar Spinal Stenosis [NCT03477955]55 participants (Actual)Interventional2006-04-30Completed
Comparison of Displacement Between Polyvinyl Chloride(PVC) and Silicon Double-Lumen Endobronchial Tubes(DLT) During Change of Position [NCT02691468]108 participants (Actual)Interventional2016-02-29Completed
Clinical Study of the Amedica Corporation Valeo OL Interbody Fusion Devices for Posterior Lumbar Interbody Fusion [NCT01557829]100 participants (Actual)Interventional2012-02-29Completed
Efficacy of the Administration of Colloidal Silicon Dioxide in Tablet Dosage Form (Carbowhite) in Patients With Acute Diarrhea. [NCT03633344]Phase 2145 participants (Actual)Interventional2016-03-29Completed
Interbody Fusion Devices in the Treatment of Cervicobrachial Syndrome; a Blinded Randomised Trial of Cancellous Structured Ceramic (CSC) Versus PEEK Cages. [NCT01511445]100 participants (Actual)Interventional2011-12-31Completed
Effect of Collagen Peptides, in Combination With Resistance Training, on Body Composition and Muscle Strength in Untrained Men [NCT06061315]80 participants (Anticipated)Interventional2023-09-15Recruiting
Randomized Controlled Trial: Prevention of Preterm Birth Using Cervical Pessary in Pregnant Women With Short Cervix (PECEP) [NCT00706264]385 participants (Actual)Interventional2007-06-30Completed
Silicon Phthalocyanine Pc4 for Photodynamic Therapy of Cutaneous T-cell Lymphoma: Single and Repeated Photoexposures [NCT01800838]Phase 111 participants (Actual)Interventional2013-04-30Completed
A Randomized, Triple-blind, Placebo-controlled Study Evaluating the Efficacy of a Novel Dietary Ingredient for Improving Hair Growth and Skin's Appearance Among Healthy Adults [NCT06010745]101 participants (Anticipated)Interventional2023-08-11Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00706264 (24) [back to overview]Preterm Premature Rupture of Membranes
NCT00706264 (24) [back to overview]Pessary Withdrawal
NCT00706264 (24) [back to overview]Pessary Repositioning Without Removal
NCT00706264 (24) [back to overview]Neonatal Death
NCT00706264 (24) [back to overview]Necrotising Enterocolitis
NCT00706264 (24) [back to overview]Intraventricular Haemorrhage
NCT00706264 (24) [back to overview]Intrauterine Fetal Demise
NCT00706264 (24) [back to overview]Gestational Age at Delivery
NCT00706264 (24) [back to overview]Composite Adverse Outcomes
NCT00706264 (24) [back to overview]Retinopathy of Prematurity
NCT00706264 (24) [back to overview]Chorioamnionitis
NCT00706264 (24) [back to overview]Cesarean Delivery
NCT00706264 (24) [back to overview]Birthweight Less Than 2500 g
NCT00706264 (24) [back to overview]Birthweight Less Than 1500 g
NCT00706264 (24) [back to overview]Any Delivery Before 34 Completed Weeks
NCT00706264 (24) [back to overview]Respiratory Distress Syndrome
NCT00706264 (24) [back to overview]Spontaneous Delivery Before 28 Completed Weeks
NCT00706264 (24) [back to overview]Spontaneous Delivery Before 34 Completed Weeks
NCT00706264 (24) [back to overview]Spontaneous Delivery Before 37 Completed Weeks
NCT00706264 (24) [back to overview]Treatment for Sepsis
NCT00706264 (24) [back to overview]Use of Antenatal Steroids
NCT00706264 (24) [back to overview]Use of Tocolysis
NCT00706264 (24) [back to overview]Vaginal Bleeding
NCT00706264 (24) [back to overview]Vaginal Discharge
NCT00763269 (4) [back to overview]Hypersensitivity Tactile(Yeaple Probe)
NCT00763269 (4) [back to overview]Air Blast Hypersensitivity (4 Week)
NCT00763269 (4) [back to overview]Air Blast Hypersensitivity (8 Week)
NCT00763269 (4) [back to overview]Hypersensitivity Tactile (Yeaple Probe)
NCT01215318 (2) [back to overview]Tampon Position Relative to the Pubococcygeal Line
NCT01215318 (2) [back to overview]Number of FDG Positive Tampoons
NCT01479127 (24) [back to overview]Degree of Fluctuation (2-12 Hours) After Administration of Oral L/C Tablets and Intra-jejunal Administration of ABT-SLV187
NCT01479127 (24) [back to overview]Mean Change From Baseline to the End of Treatment in UPDRS Total Scores and Subscores
NCT01479127 (24) [back to overview]Modified Hoehn and Yahr Staging at Baseline and End of Treatment
NCT01479127 (24) [back to overview]Number of Participants With Adverse Events (AEs), Serious AEs (SAEs), and AEs Leading to Discontinuation During the Run-in Period
NCT01479127 (24) [back to overview]Number of Participants With AEs, SAEs, and AEs Leading to Discontinuation During the ABT-SLV187 Treatment Period
NCT01479127 (24) [back to overview]Number of Participants With PCS Blood Biochemistry Results During the ABT-SLV187 Treatment Period
NCT01479127 (24) [back to overview]Number of Participants With PCS Values in Special Laboratory Parameters During the ABT-SLV187 Treatment Period
NCT01479127 (24) [back to overview]Number of Participants With Potentially Clinically Significant (PCS) Hematology Results During the ABT-SLV187 Treatment Period
NCT01479127 (24) [back to overview]Number of Participants With Potentially Clinically Significant (PCS) Vital Signs Results During the ABT-SLV187 Treatment Period
NCT01479127 (24) [back to overview]Number of Participants With Potentially Clinically Significant Urinalysis Results During the ABT-SLV187 Treatment Period
NCT01479127 (24) [back to overview]Number of Participants With Product Quality Complaints (PQC) During the ABT-SLV187 Treatment Period
NCT01479127 (24) [back to overview]Peak Plasma Concentration (Cmax), Average Plasma Concentration (Cavg), Trough Plasma Concentration (Cmin), and Cmin Within 2 and 12 Hours (Cmin [2-12 Hours]) After Administration of Oral L/C Tablets and Intra-jejunal Administration of ABT-SLV187
NCT01479127 (24) [back to overview]Schwab and England Activities of Daily Living Scale at Baseline and End of Treatment
NCT01479127 (24) [back to overview]The Area Under the Concentrations-time Curve From 0 to 12 and 0 to 16 Hours (AUC0-12, AUC0-16) After Administration of Oral L/C Tablets and Intra-jejunal Administration of ABT-SLV187
NCT01479127 (24) [back to overview]Time to Reach Peak Plasma Concentration (Tmax) After Administration of Oral Levodopa/Carbidopa (L/C) Tablets and Intra-jejunal Administration of ABT-SLV187
NCT01479127 (24) [back to overview]"Mean Change From Baseline to the End of Treatment in Percentage of Ratings in the Normal State on the Treatment Response Scale (TRS) I"
NCT01479127 (24) [back to overview]Number of Participants With Potentially Clinically Significant 12-lead Electrocardiogram (ECG) Results During the ABT-SLV187 Treatment Period
NCT01479127 (24) [back to overview]Ratio of Metabolite 3-OMD to Levodopa (M/P [AUC0-12]) After Administration of Oral L/C Tablets and Intra-jejunal Administration of ABT-SLV187
NCT01479127 (24) [back to overview]"Mean Change From Baseline to the End of Treatment in Percentage of Ratings in the OFF and Dyskinesia States on the TRS I and the Normal, OFF, and Dyskinesia States on the TRS II"
NCT01479127 (24) [back to overview]AUC0-12/Dose0-12, AUC0-16/Dose0-16 After Administration of Oral L/C Tablets and Intra-jejunal Administration of ABT-SLV187
NCT01479127 (24) [back to overview]Baseline and Endpoint (End of Treatment) Video Scoring of Unified Parkinson's Disease Rating Scale (UPDRS) Items and Dyskinesia
NCT01479127 (24) [back to overview]Change From Baseline to the End of Treatment in Parkinson's Disease Diary Assessment
NCT01479127 (24) [back to overview]Change From Baseline to the End of Treatment in the Japanese Version of Parkinson's Disease Questionnaire 39 (PDQ-39) Total Score and Domain Scores
NCT01479127 (24) [back to overview]Clinical Global Impression - Severity (CGI-S) Score at Baseline and Clinical Global Impression - Improvement (CGI-I) Score at Baseline and End of Treatment
NCT01511445 (2) [back to overview]Neck Disability Index
NCT01511445 (2) [back to overview]Fusion Status
NCT01800838 (2) [back to overview]MTD of Photodynamic Therapy
NCT01800838 (2) [back to overview]MTD of Silicon Phthalocyanine 4 Defined as the Dose Immediately Below the Dose in Which 2 or More of 6 Patients Experience a Grade 4 Toxicity Assessed Using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0
NCT02691468 (2) [back to overview]the Incidence of Clinically Significant Displacement of DLTs During Change of Patient Position
NCT02691468 (2) [back to overview]the Incidence of Critical Malposition of DLTs
NCT02903030 (7) [back to overview]Change in The Aberrant Behavior Checklist (ABC) From Baseline at Week 8
NCT02903030 (7) [back to overview]Children's Sleep Habits Questionnaire (CSHQ) at Week 8
NCT02903030 (7) [back to overview]Change in The Parenting Stress Index Short Form (PSI)
NCT02903030 (7) [back to overview]Change in Target Symptom Rating From Baseline at Week 8
NCT02903030 (7) [back to overview]Change in Social Responsiveness Scale (SRS) From Baseline at Week 8
NCT02903030 (7) [back to overview]Change in Parent Anxiety Checklist--ASD From Baseline at Week 8
NCT02903030 (7) [back to overview]Change in Gastrointestinal (GI) Module of the Pediatric Quality of Life Inventory (PedsQL) at From Baseline at Week 8
NCT02904200 (2) [back to overview]VAS Scale (0-100mm)
NCT02904200 (2) [back to overview]Changes on Peri-Wound Skin
NCT03633344 (4) [back to overview]Compliance Rate
NCT03633344 (4) [back to overview]Duration of Treatment
NCT03633344 (4) [back to overview]Quantity of Used Medication
NCT03633344 (4) [back to overview]Reduction in Frequency of Defecation to 3 Times Per Day
NCT05000047 (8) [back to overview]Subjective Feedback on the Perceived Improvement of Actual Device Fitting Using Each Impression Procedure Compared to a Non-custom Hearing Aid Fitting
NCT05000047 (8) [back to overview]Subjective Feedback of Overall Experience of Both Ear Impression Procedures
NCT05000047 (8) [back to overview]Sub-investigator Clinician Subjective Rating of Individual Potential for Improvement When Performing Each Procedure 1 (no Potential for Improvement) to 3 (a Lot of Potential for Improvement)
NCT05000047 (8) [back to overview]Sub-investigator Clinician Subjective Rating of Individual Confidence That Method of Impression Will Yield a Quality Custom Product for the Participant on a Scale From 1 (Not at All Confident) to 3 (Very Confident).
NCT05000047 (8) [back to overview]Sub-investigator Clinician Subjective Rating of Ease of Procedure on a Scale From 1 (Not at All Easy) to 10 (Most Ease)
NCT05000047 (8) [back to overview]Clinician Subjective Rating of Overall Experience of Each Procedure.
NCT05000047 (8) [back to overview]Elapsed Time in Minutes to Complete Bilateral Ear Impressions
NCT05000047 (8) [back to overview]Subjective Feedback, Pleasantness of Experience

Preterm Premature Rupture of Membranes

Number of participants who experienced rupture of membranes as diagnosed by speculum exam showing pooling, ferning, positive nitrazine test, positive amnisure test. (NCT00706264)
Timeframe: participants will be followed for the duration of pregnancy, up to nine months

InterventionParticipants (Count of Participants)
No Intervention: No Pessary17
Experimental: Pessary3

[back to top]

Pessary Withdrawal

Number of participants who experience pessary withdrawal. This outcome measure only applied to the Experimental (Pessary Arm) and no data were collected from participants in the No Intervention _(No Pessary Arm). (NCT00706264)
Timeframe: participants will be followed for the duration of pregnancy, up to nine months

InterventionParticipants (Count of Participants)
No Intervention: No Pessary0
Experimental: Pessary1

[back to top]

Pessary Repositioning Without Removal

Number of participants who required pessary repositioning without removal. This outcome measure only applied to the Experimental (Pessary Arm) and no data were collected from participants in the No Intervention _(No Pessary Arm). (NCT00706264)
Timeframe: participants will be followed for the duration of pregnancy, up to nine months

InterventionParticipants (Count of Participants)
No Intervention: No Pessary0
Experimental: Pessary27

[back to top]

Neonatal Death

The number of neonatal deaths in the pessary group was compared to those in the no pessary group (NCT00706264)
Timeframe: Between birth and 28 days of age

InterventionParticipants (Count of Participants)
No Intervention: No Pessary1
Experimental: Pessary0

[back to top]

Necrotising Enterocolitis

The number of neonatal necrotising enterocolitis in the pessary group was compared to those in the no pessary group (NCT00706264)
Timeframe: Between birth and 28 days of age

InterventionParticipants (Count of Participants)
No Intervention: No Pessary2
Experimental: Pessary0

[back to top]

Intraventricular Haemorrhage

The number of neonatal intraventricular haemorrhage in the pessary group was compared to those in the no pessary group (NCT00706264)
Timeframe: Between birth and 28 days of age

InterventionParticipants (Count of Participants)
No Intervention: No Pessary2
Experimental: Pessary0

[back to top]

Intrauterine Fetal Demise

The number of fetal deaths in the pessary group was compared to those in the no pessary group (NCT00706264)
Timeframe: Pregnancy

InterventionParticipants (Count of Participants)
No Intervention: No Pessary0
Experimental: Pessary0

[back to top]

Gestational Age at Delivery

Number of weeks of gestation completed by time of delivery (NCT00706264)
Timeframe: At time of birth

Interventionweeks (Mean)
No Intervention: No Pessary34.9
Experimental: Pessary37.7

[back to top]

Composite Adverse Outcomes

The number of neonatal cases with composite adverse outcomes in the pessary group was compared to those in the no pessary group (NCT00706264)
Timeframe: Between birth and 28 days of age

InterventionParticipants (Count of Participants)
No Intervention: No Pessary30
Experimental: Pessary5

[back to top]

Retinopathy of Prematurity

The number of neonatal retinopathy in the pessary group was compared to those in the no pessary group (NCT00706264)
Timeframe: Between birth and 28 days of age

InterventionParticipants (Count of Participants)
No Intervention: No Pessary2
Experimental: Pessary0

[back to top]

Chorioamnionitis

Number of participants that showed intrauterine infection diagnosed by maternal tachycardia, fever, uterine tenderness, purulent or abnormal cervical discharge, fetal tachycardia. (NCT00706264)
Timeframe: participants will be followed for the duration of pregnancy, up to nine months

InterventionParticipants (Count of Participants)
No Intervention: No Pessary6
Experimental: Pessary5

[back to top]

Cesarean Delivery

Number of participants that underwent cesarean delivery (NCT00706264)
Timeframe: At time of delivery

InterventionParticipants (Count of Participants)
No Intervention: No Pessary40
Experimental: Pessary41

[back to top]

Birthweight Less Than 2500 g

Number of newborns whose birthweight is less than 2500 grams (NCT00706264)
Timeframe: Time of delivery

InterventionParticipants (Count of Participants)
Expectant Management56
Placement of Arabin Pessary Since 23 Weeks Until 37 Weeks17

[back to top]

Birthweight Less Than 1500 g

Number of newborns whose birthweight is less than 1500 grams (NCT00706264)
Timeframe: Time of delivery

InterventionParticipants (Count of Participants)
No Intervention: No Pessary26
Experimental: Pessary9

[back to top]

Any Delivery Before 34 Completed Weeks

Number of all preterm births before 34 weeks occurred in each group. (NCT00706264)
Timeframe: Between 24 and 34 weeks

InterventionParticipants (Count of Participants)
No Intervention: No Pessary53
Experimental: Pessary14

[back to top]

Respiratory Distress Syndrome

The number of neonatal Respiratory distress syndrome in the pessary group was compared to those in the no pessary group (NCT00706264)
Timeframe: Between birth and 28 days of age

InterventionParticipants (Count of Participants)
No Intervention: No Pessary23
Experimental: Pessary5

[back to top]

Spontaneous Delivery Before 28 Completed Weeks

Number of preterm births before 28 weeks occurred in each group. (NCT00706264)
Timeframe: Between 24 and 28 weeks

InterventionParticipants (Count of Participants)
No Intervention: No Pessary16
Experimental: Pessary4

[back to top]

Spontaneous Delivery Before 34 Completed Weeks

Number of spontaneous preterm births before 34 weeks occurred in each group. (NCT00706264)
Timeframe: Between 24 and 34 weeks

InterventionParticipants (Count of Participants)
No Intervention: No Pessary51
Experimental: Pessary12

[back to top]

Spontaneous Delivery Before 37 Completed Weeks

Number of preterm births before 37 weeks occurred in each group. (NCT00706264)
Timeframe: Between 24 and 37 weeks

InterventionParticipants (Count of Participants)
No Intervention: No Pessary113
Experimental: Pessary41

[back to top]

Treatment for Sepsis

The number of neonatal cases of treatment needed for sepsis in the pessary group was compared to those in the no pessary group (NCT00706264)
Timeframe: Between birth and 28 days of age

InterventionParticipants (Count of Participants)
No Intervention: No Pessary12
Experimental: Pessary3

[back to top]

Use of Antenatal Steroids

Number of participants that received betamethasone to reduce morbidity of expected preterm delivery (NCT00706264)
Timeframe: participants will be followed for the duration of pregnancy, up to nine months

InterventionParticipants (Count of Participants)
No Intervention: No Pessary121
Experimental: Pessary80

[back to top]

Use of Tocolysis

Number of participants required use of tocolytic medication (NCT00706264)
Timeframe: participants will be followed for the duration of pregnancy, up to nine months

InterventionParticipants (Count of Participants)
No Intervention: No Pessary101
Experimental: Pessary64

[back to top]

Vaginal Bleeding

Number of participants who experienced bleeding from lower genital tract during antepartum period (NCT00706264)
Timeframe: participants will be followed for the duration of pregnancy, up to nine months

InterventionParticipants (Count of Participants)
No Intervention: No Pessary9
Experimental: Pessary7

[back to top]

Vaginal Discharge

Number of participants who experienced an increased vaginal discharge. (NCT00706264)
Timeframe: participants will be followed for the duration of pregnancy, up to nine months

InterventionParticipants (Count of Participants)
No Intervention: No Pessary87
Experimental: Pessary190

[back to top]

Hypersensitivity Tactile(Yeaple Probe)

Measured with an electronic force sensing probe (Yeaple Probe): 10, 20, 30, 40, up to 50 grams of force are applied to hypersensitive tooth until pain elicited. Grams of force needed to elicit pain are recorded as hypersensitivity score for the tooth. For Tactile Hypersensitivity: The higher the score (the more grams of force needed to elicit a response of pain), the lower the hypersensitivity. Hypersensitivity scores on a per study subject basis are recorded as mean scores of two hypersensitive teeth (NCT00763269)
Timeframe: 4 weeks

Interventionunits on a scale (Mean)
A-Experimental Toothpatse19.81
B -Control Toothpaste13.94

[back to top]

Air Blast Hypersensitivity (4 Week)

"Examiner rates the response to stimulation of hypersensitive teeth using a jet of air (constant stimulus on the basis of duration, pressure, temperature, distance from target). Response is rated based on the Schiff Cold Air Sensitivity Scale.This analog scale scores for the tooth is 0,1,2 or 3:0No subject response to stimulus1responds but will continue2responds and moves or requests discontinuation3Painful response to stimulus, discontinuation requested. The lower the score, the lower the hypersensitivity.Scores per study subject are recorded as mean scores of two hypersensitive teeth." (NCT00763269)
Timeframe: 4 weeks

Interventionunits on a scale (Mean)
A-Experimental Toothpatse1.61
B -Control Toothpaste2.18

[back to top]

Air Blast Hypersensitivity (8 Week)

"Examiner rates the response to stimulation of hypersensitive teeth using a jet of air (constant stimulus on the basis of duration, pressure, temperature, distance from target). Response is rated based on the Schiff Cold Air Sensitivity Scale.This analog scale scores for the tooth is 0,1,2 or 3:0No subject response to stimulus1responds but will continue2responds and moves or requests discontinuation3Painful response to stimulus, discontinuation requested. The lower the score, the lower the hypersensitivity.Scores per study subject are recorded as mean scores of two hypersensitive teeth." (NCT00763269)
Timeframe: 8 weeks

Interventionunits on a scale (Mean)
A-Experimental Toothpatse0.89
B -Control Toothpaste1.80

[back to top]

Hypersensitivity Tactile (Yeaple Probe)

Measured with an electronic force sensing probe (Yeaple Probe): 10, 20, 30, 40, up to 50 grams of force are applied to hypersensitive tooth until pain elicited. Grams of force needed to elicit pain are recorded as hypersensitivity score for the tooth. For Tactile Hypersensitivity: The higher the score (the more grams of force needed to elicit a response of pain), the lower the hypersensitivity. Hypersensitivity scores on a per study subject basis are recorded as mean scores of two hypersensitive teeth (NCT00763269)
Timeframe: 8 weeks

InterventionUnits on a scale (Mean)
A-Experimental Toothpatse31.90
B -Control Toothpaste17.28

[back to top]

Tampon Position Relative to the Pubococcygeal Line

measure tampon position in regard to the pubococcygeal line to identify if positioning is responsible for urinary contamination. (NCT01215318)
Timeframe: 1 month

Interventionmm (Mean)
Modified Vaginal Tampons5.9
Unmodified Vaginal Tampons5.1

[back to top]

Number of FDG Positive Tampoons

Number of FDG positive Tampoons with an SUV > 3 (NCT01215318)
Timeframe: 1 month

InterventionFDG positive tampons (Number)
Modified Vaginal Tampons2
Unmodified Vaginal Tampons10

[back to top]

Degree of Fluctuation (2-12 Hours) After Administration of Oral L/C Tablets and Intra-jejunal Administration of ABT-SLV187

Degree of Fluctuation (calculated as [Cmax - Cmin] / Cavg)) of levodopa, carbidopa, and 3-OMD after administration of the oral L/C tablets (Day -1) and intra-jejunal administration of ABT-SLV187 (Day 21). (NCT01479127)
Timeframe: Baseline (Day -1), End of ABT-SLV187 Treatment Period (Day 21)

,
Interventionratio (Mean)
LevodopaCarbidopa3-OMD
Levodopa-carbidopa Intestinal Gel0.380.780.35
Oral Levodopa-carbidopa Tablets2.10.970.48

[back to top]

Mean Change From Baseline to the End of Treatment in UPDRS Total Scores and Subscores

The UPDRS is an Investigator-used rating tool to follow the longitudinal course of Parkinson's disease. The total score is the sum of the responses to the 31 questions (44 answers) that comprise Parts I-III of the scale. The total score ranges from 0-176, with 176 representing the worst (total) disability, and 0 no disability. The Part I Score is the sum of the answers to the 4 questions related to Mentation, Behavior and Mood, and ranges from 0-16. The Part II score is the sum of the answers to the 13 questions related to Activities of Daily Living, and ranges from 0-52. The Part III score is the sum of the 27 answers related to Motor Examination, and ranges from 0-108. The Part IV Score is the sum of the answers to the 11 questions related to Complications of Therapy, and ranges from 0-23. The Part IV dyskinesia subscore ranges from 0-12. For each part of the UPDRS, higher scores are associated with more disability. (NCT01479127)
Timeframe: Baseline (Day -1), End of ABT-SLV187 Treatment Period (Day 21)

Interventionunits on a scale (Mean)
Total scorePart IPart IIPart II (Off-time)Part IIIPart IV subscore of dyskinesia
Levodopa-carbidopa Intestinal Gel-0.600.200.60-2.20-1.402.20

[back to top]

Modified Hoehn and Yahr Staging at Baseline and End of Treatment

Participant's ON and OFF states staged according to the Modified Hoehn and Yahr criteria, an 8-point scale for staging: 0, No signs of disease; 1, Unilateral disease; 1.5, Unilateral plus axial involvement; 2, Bilateral disease; 2.5, Mild bilateral disease; 3, Mild to moderate bilateral disease; 4, Severe disability; and 5, Wheelchair bound or bedridden unless aided. ON time is when PD symptoms are well controlled by the drug. OFF time is when PD symptoms are not adequately controlled by the drug. (NCT01479127)
Timeframe: Baseline (Day -1), End of ABT-SLV187 Treatment Period (Day 21)

Interventionunits on a scale (Median)
ON state staging, BaselineON state staging, EndpointOFF state staging, BaselineOFF state staging, Endpoint
Levodopa-carbidopa Intestinal Gel2.53.04.04.0

[back to top]

Number of Participants With Adverse Events (AEs), Serious AEs (SAEs), and AEs Leading to Discontinuation During the Run-in Period

AE: any untoward medical occurrence in a participant that does not necessarily have a causal relationship with this treatment. SAE: an event that results in the death of a subject, is life threatening, results in hospitalization or prolongation of hospitalization, is a congenital anomaly, results in persistent or significant disability/incapacity, or other important medical event. Severity was rated as mild, moderate, or severe. AEs of special interest included: device-associated gastrointestinal disorders; cardiovascular fatalities; aspiration including aspiration pneumonia; a diagnosis of peripheral polyneuropathy (axonal, demyelinating or mixed type); possible symptoms of peripheral polyneuropathy; clinically significant weight loss. 'AEs at least possibly related' are defined as those that were assessed by investigator as probably related or possibly related. (NCT01479127)
Timeframe: During the Run-in period (up to approximately 28 days)

Interventionparticipants (Number)
AEAE at least possibly related to study drug/deviceSevere AESAEAE leading to discontinuation of study drugSAE at least possibly drug or drug device-relatedAE of special interestAE caused by study drugAE caused by devicesAE caused by NJ tube insertionFatal AE
Oral Levodopa/Carbidopa Tablet75001005NANA0

[back to top]

Number of Participants With AEs, SAEs, and AEs Leading to Discontinuation During the ABT-SLV187 Treatment Period

AE: any untoward medical occurrence in a participant that does not necessarily have a causal relationship with this treatment. SAE: an event that results in the death of a subject, is life threatening, results in hospitalization or prolongation of hospitalization, is a congenital anomaly, results in persistent or significant disability/incapacity, or other important medical event. Severity was rated as mild, moderate, or severe. AEs of special interest included: device-associated gastrointestinal disorders; cardiovascular fatalities; aspiration including aspiration pneumonia; a diagnosis of peripheral polyneuropathy (axonal, demyelinating or mixed type); possible symptoms of peripheral polyneuropathy; clinically significant weight loss. 'AEs at least possibly related' are defined as those that were assessed by investigator as probably related or possibly related. (NCT01479127)
Timeframe: From NJ placement to end of ABT-SLV187 Treatment Period (Day 21) +30 days

Interventionparticipants (Number)
AEAE at least possibly related to study drug/deviceSevere AESAEAE leading to discontinuation of study drugSAE at least possiby drug or drug device-relatedAE of special interestAE caused by study drugAE caused by devicesAE caused by NJ tube insertionFatal AE
Levodopa-carbidopa Intestinal Gel43111123010

[back to top]

Number of Participants With PCS Blood Biochemistry Results During the ABT-SLV187 Treatment Period

M=male, F=female, γ-GTP=gamma-glutamyl transpeptidase. (NCT01479127)
Timeframe: Baseline (Day -1), End of ABT-SLV187 Treatment Period (Day 21)

Interventionparticipants (Number)
Low PCS Blood urea nitrogen [mg/dL]: 6High PCS Blood urea nitrogen [mg/dL]: 20Low Creatinine [mg/dL]: 0.61 M / 0.47 FHigh Creatinine [mg/dL]: 1.04 M / 0.79 FLow PCS Total bilirubin [mg/dL]: 0.2High PCS Total bilirubin [mg/dL]: 1.0Low PCS Alanine aminotransferase [U/L]: 5High PCS Alanine aminotransferase [U/L]: 40Low PCS Aspartate aminotransferase [U/L]: 10High PCS Aspartate aminotransferase [U/L]: 40Low PCS Alkaline phosphatase [U/L]: 115High PCS Alkaline phosphatase [U/L]: 359Low PCS γ-GTP [U/L]: 0High PCS γ-GTP [U/L]: 70 M / 30 FLow PCS Sodium [mEq/L]: 136High PCS Sodium [mEq/L]: 147Low PCS Potassium [mEq/L]: 3.6High PCS Potassium [mEq/L]: 5.0Low PCS Calcium [mg/dL]: 8.7High PCS Calcium [mg/dL]: 10.1Low PCS Chloride [mEq/L]: 98High PCS Chloride [mEq/L]: 109Low PCS Magnesium [mg/dL]: 1.8High PCS Magnesium [mg/dL]: 2.6Low PCS Inorganic Phosphors [mg/dL]: 2.4High PCS Inorganic Phosphors [mg/dL]: 4.3Low PCS Uric acid [mg/dL]: 3.7 M / 2.5 FHigh PCS Uric acid [mg/dL]: 7 M / 7.0 FLow PCS Total cholesterol [mg/dL]: 150High PCS Total cholesterol [mg/dL]: 219Low PCS Total protein [g/dL]: 6.7High PCS Total protein [g/dL]: 8.3Low PCS Albumin [g/dL]: 4.0High PCS Albumin [g/dL]: 5.0Low PCS Glucose [mg/dL]: 70High PCS Glucose [mg/dL]: 109Low PCS Triglycerides [mg/dL]: 50High PCS Triglycerides [mg/dL]: 149Low PCS Creatine kinase [U/L]: 57 M / 32 FHigh PCS Creatine kinase [U/L]: 197 M / 180 FLow PCS Bicarbonate [mEq/L]: 22High PCS Bicarbonate [mEq/L]: 29Low PCS Lactate dehydrogenase [U/L]: 115High PCS Lactate dehydrogenase [U/L]: 245
Levodopa-carbidopa Intestinal Gel01200000100100100030100101200250300110130001

[back to top]

Number of Participants With PCS Values in Special Laboratory Parameters During the ABT-SLV187 Treatment Period

M=male, F=female (NCT01479127)
Timeframe: Baseline (Day -1), End of ABT-SLV187 Treatment Period (Day 21)

Interventionparticipants (Number)
Low PCS Vitamin B6 pyridoxamine [ng/mL]: Low PCS Vitamin B6 pyridoxal [ng/mL]: 6.0 M/4.0 FHigh PCS Vitamin B6 pyridoxal [ng/mL]: 40 M / 19 FLow PCS Vitamin B6 pyridoxine [ng/mL]: Low PCS Vitamin B12 [pg/mL]: 180High PCS Vitamin B12 [pg/mL]: 914Low PCS Homocysteine [nmol/mL]: 3.7High PCS Homocysteine [nmol/mL]: 13.5Low PCS Folic acid [ng/mL]: < 3.1
Levodopa-carbidopa Intestinal Gel041010041

[back to top]

Number of Participants With Potentially Clinically Significant (PCS) Hematology Results During the ABT-SLV187 Treatment Period

M=male, F=female, MCV=mean corpuscular volume, MCH=mean corpuscular hemoglobin, MCHC=mean corpuscular hemoglobin concentration. (NCT01479127)
Timeframe: Baseline (Day -1), End of ABT-SLV187 Treatment Period (Day 21)

Interventionparticipants (Number)
Low PCS Hematocrit [%]: 39.8 M / 33.4 FHigh PCS Hematocrit [%]: 51.8 M / 44.9 FLow PCS Hemoglobin [g/dL]: 13.5 M / 11.3 FHigh PCS Hemoglobin [g/dL]: 17.6 M / 15.2 FLow PCS RBC Count [*10^4/µL]: 427 M / 376 FHigh PCS RBC Count [*10^4/µL]: 570 M / 500 FLow PCS WBC Count [/µL]: 3900 M / 3500 FHigh PCS WBC Count [/µL]: 9800 M / 9100 FLow PCS Neutrophils [%]: 40.0High PCS Neutrophils [%]: 74.0Low PCS Lymphocytes [%]: 18.0High PCS Lymphocytes [%]: 59.0Low PCS Monocytes [%]: 0.0High PCS Monocytes [%]: 8.0Low PCS Basophils [%]: 0.0High PCS Basophils [%]: 2.0Low PCS Eosinophils [%]: 0.0High PCS Eosinophils [%]: 6.0Low PCS Platelet count [*10^4/µL]: 13.1 M / 13.0 FHigh PCS Platelet count [*10^4/µL]: 36.2 M/ 36.9 FLow PCS MCV [FL]: 82.7 M / 79.0 FHigh PCS MCV [FL]: 101.6 M / 100.0 FLow PCS MCH [Pg]: 28 M / 26.3 FHigh PCS MCH [Pg]: 34.6 M / 34.3 FLow PCS MCHC [%]: 31.6 M / 30.7 FHigh PCS MCHC [%]: 36.6 M / 36.6 F
Levodopa-carbidopa Intestinal Gel30303010000001000001000010

[back to top]

Number of Participants With Potentially Clinically Significant (PCS) Vital Signs Results During the ABT-SLV187 Treatment Period

↓=decrease, ↑=increase, BL=baseline, temp.=temperature, SBP=systolic blood pressure, Sup.=supine, Sta.=standing, DBP=diastolic blood pressure. (NCT01479127)
Timeframe: Baseline (Day -1), End of ABT-SLV187 Treatment Period (Day 21)

Interventionparticipants (Number)
Low PCS Weight [kg]: ≥7% ↓ from BLHigh PCS Weight [kg]: ≥7% ↑ from BLHigh PCS Body temp. [⁰C]: ≥38.8 and ≥1.1 ↑ from BLLow PCS SBP Sup. [mmHg]: ≤90 and >30 ↓ from BLHigh PCS SBP Sup. [mmHg]: ≥180 and >40 ↑ from BLLow PCS SBP Sta. [mmHg]: ≤90 and >30 ↓ from BLHigh PCS SBP Sta. [mmHg]: ≥180 and >40 ↑ from BLLow PCS SBP Orthostatic [mmHg]: ↓ of ≥30 in SBPLow PCS DBP Sup. [mmHg]: ≤50 and >30 ↓ from BLHigh PCS DBP Sup. [mmHg]: ≥105 and >30 ↑ from BLLow PCS DBP Sta. [mmHg]: ≤50 and >30 ↓ from BLHigh PCS DBP Sta. [mmHg]: ≥105 and >30 ↑ from BLLow PCS DBP Orthostatic [mmHg]: ↓ of ≥20 in DBPPulse rate [bpm]: ≤50 and >30 ↓ from BLPulse rate [bpm]: ≥120 and >30 ↑ from BL
Levodopa-carbidopa Intestinal Gel000001010000100

[back to top]

Number of Participants With Potentially Clinically Significant Urinalysis Results During the ABT-SLV187 Treatment Period

(NCT01479127)
Timeframe: Baseline (Day -1), End of ABT-SLV187 Treatment Period (Day 21)

Interventionparticipants (Number)
Low PCS Specific gravity: 1.002High PCS Specific gravity: 1.030Low PCS pH: 4.5High PCS pH: 8.0High PCS Protein: > traceHigh PCS Glucose: > traceHigh PCS Occult blood: > negativeHigh PCS Ketone: > negative
Levodopa-carbidopa Intestinal Gel00010000

[back to top]

Number of Participants With Product Quality Complaints (PQC) During the ABT-SLV187 Treatment Period

(NCT01479127)
Timeframe: Baseline (Day -1), End of ABT-SLV187 Treatment Period (Day 21)

Interventionparticipants (Number)
Any PQCAny PQC related to an AEAny serious PQCAny PQC leading to discontinuation of study drugAny PQC by pumpAny PQC by NJ-tube insertionAny PQC by adapterAny PQC by cassettesWithout any PQCs
Levodopa-carbidopa Intestinal Gel200002014

[back to top]

Peak Plasma Concentration (Cmax), Average Plasma Concentration (Cavg), Trough Plasma Concentration (Cmin), and Cmin Within 2 and 12 Hours (Cmin [2-12 Hours]) After Administration of Oral L/C Tablets and Intra-jejunal Administration of ABT-SLV187

Cmax, Cavg, Cmin, and Cmin (2-12 hours) of levodopa, carbidopa, and 3-OMD after administration of the oral L/C tablets (Day -1) and intra-jejunal administration of ABT-SLV187 (Day 21). Cmin values for levodopa and carbidopa during the 16 hours of infusion were observed either at time 0 or 15 min after start of the infusion and were a result of drug washout prior to establishment of infusion. (NCT01479127)
Timeframe: Baseline (Day -1), End of ABT-SLV187 Treatment Period (Day 21)

,
Interventionµg/mL (Mean)
Cmax: LevodopaCmax: CarbidopaCmax: 3-OMDCavg: LevodopaCavg: CarbidopaCavg: 3-OMDCmin: LevodopaCmin: CarbidopaCmin: 3-OMDCmin (2-12 hours): LevodopaCmin (2-12 hours):CarbidopaCmin (2-12 hours): 3-OMD
Levodopa-carbidopa Intestinal Gel4.380.27311.72.870.1729.800.0610.0167.782.380.1308.14
Oral Levodopa-carbidopa Tablets5.960.1289.272.370.0797.360.2680.0145.670.7340.0505.72

[back to top]

Schwab and England Activities of Daily Living Scale at Baseline and End of Treatment

The Schwab and England scale was used to rate the subject's activities of daily living by recording the percentage score, ranging between being completely independent (100%) and totally dependent (10%). (NCT01479127)
Timeframe: Baseline (Day -1), End of ABT-SLV187 Treatment Period (Day 21)

Interventionunits on a scale (Median)
BaselineEndpoint
Levodopa-carbidopa Intestinal Gel80.080.0

[back to top]

The Area Under the Concentrations-time Curve From 0 to 12 and 0 to 16 Hours (AUC0-12, AUC0-16) After Administration of Oral L/C Tablets and Intra-jejunal Administration of ABT-SLV187

AUC0-12 and AUC0-16 of levodopa, carbidopa, and 3-OMD after administration of the oral L/C tablets (Day -1) and intra-jejunal administration of ABT-SLV187 (Day 21). (NCT01479127)
Timeframe: Baseline (Day -1), End of ABT-SLV187 Treatment Period (Day 21)

,
Interventionµg*h/mL (Mean)
AUC0-12: LevodopaAUC0-12: CarbidopaAUC0-12: 3-OMDAUC0-16: LevodopaAUC0-16: CarbidopaAUC0-16: 3-OMD
Levodopa-carbidopa Intestinal Gel34.42.0711846.72.80165
Oral Levodopa-carbidopa Tablets28.40.9488.3NANANA

[back to top]

Time to Reach Peak Plasma Concentration (Tmax) After Administration of Oral Levodopa/Carbidopa (L/C) Tablets and Intra-jejunal Administration of ABT-SLV187

Tmax of levodopa, carbidopa, and its metabolite 3-O-methyldopa (3-OMD) after administration of oral L/C tablets and intra-jejunal administration of ABT-SLV187. (NCT01479127)
Timeframe: Baseline (Day -1): pre-dose; 15, 30, 45, 60 mins post-morning dose; every 30 mins thereafter for 12 hrs. Day 21: pre-dose; 15, 30, 45, 60 mins post-infusion; every 30 mins from hrs 1 to 12 post-infusion; every 2 hrs from 12 to 16 hrs post-infusion.

,
Interventionhours (Mean)
LevodopaCarbidopa3-OMD
Levodopa-carbidopa Intestinal Gel1.04.511
Oral Levodopa-carbidopa Tablets3.07.811

[back to top]

"Mean Change From Baseline to the End of Treatment in Percentage of Ratings in the Normal State on the Treatment Response Scale (TRS) I"

"Participants were video recorded a total of 10 times for 1 to 2 minutes every 60 minutes while performing a standardized sequence of motor tasks: rest, finger taps, rapid alternating movement of hands, arising from chair and gait, including confirmation of postural stability. Based on these video recordings, a Video Evaluation Committee consisting of 3 neurologists individually evaluated the following Video Assessment and Treatment Response Scale (TRS) under blinded conditions: Finger Taps, Rapid Alternating Movement of Hands, Arising from Chair, Gait, Body Bradykinesia and Hypokinesia, Dyskinesia. The average of the neurologists' evaluations was calculated as a percentage of ratings in the Normal state (ie, mild OFF to ON with mild dyskinesia) on the TRS I (total 10 assessments per day)." (NCT01479127)
Timeframe: Baseline (Day -1), End of ABT-SLV187 Treatment Period (Day 21)

Interventionpercentage of ratings (Mean)
Levodopa-carbidopa Intestinal Gel15.33

[back to top]

Number of Participants With Potentially Clinically Significant 12-lead Electrocardiogram (ECG) Results During the ABT-SLV187 Treatment Period

High potentially clinically significant Bazett's heart rate-corrected QT interval (QTcB) values were: 450 msec for males / 470 msec for females. (NCT01479127)
Timeframe: Baseline (Day -1), End of ABT-SLV187 Treatment Period (Day 21)

Interventionparticipants (Number)
Levodopa-carbidopa Intestinal Gel0

[back to top]

Ratio of Metabolite 3-OMD to Levodopa (M/P [AUC0-12]) After Administration of Oral L/C Tablets and Intra-jejunal Administration of ABT-SLV187

M/P (AUC0-12) after administration of the oral L/C tablets (Day -1) and intra-jejunal administration of ABT-SLV187 (Day 21). (NCT01479127)
Timeframe: Baseline (Day -1), End of ABT-SLV187 Treatment Period (Day 21)

Interventionratio (Mean)
Oral Levodopa-carbidopa Tablets3.11
Levodopa-carbidopa Intestinal Gel3.53

[back to top]

"Mean Change From Baseline to the End of Treatment in Percentage of Ratings in the OFF and Dyskinesia States on the TRS I and the Normal, OFF, and Dyskinesia States on the TRS II"

"Participants were video recorded a total of 10 times for 1 to 2 minutes every 60 minutes while performing a standardized sequence of motor tasks: rest, finger taps, rapid alternating movement of hands, arising from chair and gait, including confirmation of postural stability. Based on these video recordings, a Video Evaluation Committee consisting of 3 neurologists individually evaluated the following Video Assessment and TRS under blinded conditions: Finger Taps, Rapid Alternating Movement of Hands, Arising from Chair, Gait, Body Bradykinesia and Hypokinesia, Dyskinesia for TRS I, with the addition of Tremor at Rest and Postural Stability for TRS II. The average of the 3 neurologists' evaluations was calculated as a percentage of ratings in the Normal state (ie, mild OFF to ON with mild dyskinesia), the Off state (moderate OFF to severe OFF), and the Dyskinesia state (ON with moderate dyskinesia to ON with severe dyskinesia) on the TRS I or II." (NCT01479127)
Timeframe: Baseline (Day -1), End of ABT-SLV187 Treatment Period (Day 21)

Interventionpercentage of ratings (Mean)
"TRS I OFF state""TRS I Dyskinesia state""TRS II Normal state""TRS II OFF state""TRS II Dyskinesia state"
Levodopa-carbidopa Intestinal Gel-15.330.0014.67-15.330.67

[back to top]

AUC0-12/Dose0-12, AUC0-16/Dose0-16 After Administration of Oral L/C Tablets and Intra-jejunal Administration of ABT-SLV187

AUC0-12/Dose0-12 of levodopa, carbidopa, and 3-OMD after administration of the oral L/C tablets (Day -1) and intra-jejunal administration of ABT-SLV187 (Day 21). AUC0-16/Dose0-16 of levodopa, carbidopa, and 3-OMD after administration of intra-jejunal administration of ABT-SLV187 (Day 21). (NCT01479127)
Timeframe: Baseline (Day -1), End of ABT-SLV187 Treatment Period (Day 21)

,
Interventionµg*h/mL/mg (Mean)
AUC0-12/Dose0-12: LevodopaAUC0-12/Dose0-12: CarbidopaAUC0-12/Dose0-12: 3-OMDAUC0-16/Dose0-16: LevodopaAUC0-16/Dose0-16: CarbidopaAUC0-16/Dose0-16: 3-OMD
Levodopa-carbidopa Intestinal Gel0.0320.0080.1130.0350.0080.125
Oral Levodopa-carbidopa Tablets0.0360.0120.112NANANA

[back to top]

Baseline and Endpoint (End of Treatment) Video Scoring of Unified Parkinson's Disease Rating Scale (UPDRS) Items and Dyskinesia

Participants were video recorded a total of 10 times for 1 to 2 minutes every 60 minutes while performing a standardized sequence of motor tasks. Based on these video recordings, a Video Evaluation Committee consisting of 3 neurologists individually evaluated the video under blinded conditions using the following assessments: Tremor at Rest (UPDRS item #20), Finger Taps (UPDRS #23), Rapid Alternating Movement of Hands (UPDRS #25), Arising from Chair (UPDRS #27), Gait (UPDRS #29), Postural Stability (UPDRS #30), Body Bradykinesia and Hypokinesia (UPDRS #31), and Dyskinesia (evaluated with the Goetz Dyskinesia Rating Scale). The UPDRS score is the sum of the answers to individual questions, each of which are measured on a 5-point scale (0-4), with higher scores associated with more disability. The Goetz Dyskinesia Rating Scale is a 5-point scale of the severity of dyskinesias, from 0 (absent) to 4 (violent dyskinesias). (NCT01479127)
Timeframe: Baseline (Day -1), Endpoint (Day 21)

Interventionunits on a scale (Mean)
Tremor at rest, BaselineTremor at rest, EndpointFinger taps, BaselineFinger taps, EndpointRapid alternating movement of hands, BaselineRapid alternating movement of hands, EndpointArising from chair, BaselineArising from chair, EndpointGait, BaselineGait, EndpointPostural stability, BaselinePostural stability, EndpointBody bradykinesia and hypokinesia, BaselineBody bradykinesia and hypokinesia, EndpointDyskinesia, Baseline
Levodopa-carbidopa Intestinal Gel0.000.000.400.401.000.600.100.000.600.601.601.101.000.800.400.90

[back to top]

Change From Baseline to the End of Treatment in Parkinson's Disease Diary Assessment

For each half hour period during 3 consecutive days prior to each assessment of the diary, participants (and/or their caregivers) entered into a diary whether they were asleep, in the ON motor state or in the OFF motor state in the following 5 grades: asleep, OFF, ON (no dyskinesia [D]), ON with non-troublesome dyskinesia (NTD), ON with troublesome dyskinesia (TD). ON time is when PD symptoms are well controlled by the drug. OFF time is when PD symptoms are not adequately controlled by the drug. Dyskinetic time is time with involuntary muscle movement. The ON or OFF times were calculated as the average of 3 daily times from the diaries. w/o = without, w/ = with (NCT01479127)
Timeframe: Baseline (Day -1), End of ABT-SLV187 Treatment Period (Day 21)

Interventionhours (Mean)
Daily OFF timeDaily ON time w/o D + time w/ NTDDaily ON time w/o D + time w/ NTD + time w/ TD
Levodopa-carbidopa Intestinal Gel-1.020.761.02

[back to top]

Change From Baseline to the End of Treatment in the Japanese Version of Parkinson's Disease Questionnaire 39 (PDQ-39) Total Score and Domain Scores

The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing 8 domains of health in Parkinson's disease patients, including Mobility, Activities of Daily Living, Emotional Well-being, Stigma, Social Support, Cognition, Communication, and Bodily Discomfort, as well as a Summary Index Total Score. Scores for each are on a scale from 0 to 100, where lower scores indicate a better perceived health status. Higher scores are consistently associated with the more severe symptoms of the disease such as tremor and stiffness. (NCT01479127)
Timeframe: Baseline (Day -1), End of ABT-SLV187 Treatment Period (Day 21)

Interventionunits on a scale (Mean)
Total scoreDomain: MobilityDomain: Activities of daily livingDomain: Emotional well-beingDomain: StigmaDomain: Social supportDomain: CognitionDomain: CommunicationDomain: Bodily discomfort
Levodopa-carbidopa Intestinal Gel1.2610.00-0.83-8.331.25-5.00-5.001.678.33

[back to top]

Clinical Global Impression - Severity (CGI-S) Score at Baseline and Clinical Global Impression - Improvement (CGI-I) Score at Baseline and End of Treatment

The CGI-S is a global assessment by the Investigator of current symptomatology and impact of illness on functioning. The ratings of the CGI-S are as follows: normal, borderline ill, mildly ill, moderately ill, markedly ill, severely ill, and among the most extremely ill. The CGI-I is a global assessment by the Investigator of the change in clinical status since the start of treatment. The CGI-I ratings are as follows: very much improved, much improved, minimally improved, no change, minimally worse, much worse, very much worse. (NCT01479127)
Timeframe: Baseline (Day -1), End of ABT-SLV187 Treatment Period (Day 21)

Interventionparticipants (Number)
CGI-S, Baseline: NormalCGI-S, Baseline: Borderline illCGI-S, Baseline: Mildly illCGI-S, Baseline: Moderately illCGI-S, Baseline: Markedly illCGI-S, Baseline: Severely illCGI-S, Baseline: Among the most extremely illCGI-S, Endpoint: NormalCGI-S, Endpoint: Borderline illCGI-S, Endpoint: Mildly illCGI-S, Endpoint: Moderately illCGI-S, Endpoint: Markedly illCGI-S, Endpoint: Severely illCGI-S, Endpoint: Among the most extremely illCGI-I: Very much improvedCGI-I: Much improvedCGI-I: Minimally improvedCGI-I: No changeCGI-I: Minimally worseCGI-I: Much worseCGI-I: Very much worse
Levodopa-carbidopa Intestinal Gel000230010031001310000

[back to top]

Neck Disability Index

The change in the Neck Disability Index compared to the pre-op value for each group will be compared. Neck disability index is a unitless measure from zero (no disability) to 100 (absolute disability). Change is calculated as the pre-op value minus the 24 month value. A negative difference indicates that the patient is more disabled at 24 months. (NCT01511445)
Timeframe: 24 months post-op

Interventionunits on a scale from 0 to 100 (Mean)
ACDF With Valeo CSC Ceramic Cage17.9
ACDF With PEEK Interbody Cage16.7

[back to top]

Fusion Status

Dynamic flexion-extension plane film x-rays will be used to assess fusion at all four follow-up periods. The criteria for fusion are rotation motion less than or equal to four degrees and translation less than 1.25 mm. The final fusion judgement will be fusion status at 24 months or the last time point with flexion-extension data available. (NCT01511445)
Timeframe: 3 mo., 6mo., 12 mo., 24 months

InterventionParticipants (Count of Participants)
ACDF With Valeo CSC Ceramic Cage40
ACDF With PEEK Interbody Cage37

[back to top]

MTD of Photodynamic Therapy

Defined as the dose immediately below the dose in which 2 or more of 6 patients experience a grade 4 toxicity assessed using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. (NCT01800838)
Timeframe: Up to 30 days

InterventionJ/cm^2 (Number)
Treatment (Silicon Phthalocyanine 4 and PDT)150

[back to top]

MTD of Silicon Phthalocyanine 4 Defined as the Dose Immediately Below the Dose in Which 2 or More of 6 Patients Experience a Grade 4 Toxicity Assessed Using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0

(NCT01800838)
Timeframe: Up to 30 days

Interventionmg/ml (Number)
Treatment (Silicon Phthalocyanine 4 and PDT)0.1

[back to top]

the Incidence of Clinically Significant Displacement of DLTs During Change of Patient Position

The tracheal distance was defined as the distance between the distal tip of the tracheal lumen and tracheal carina whereas the bronchial distance was defined as that between the bronchial carina and distal tip of endobronchial lumen. The displacement of DLT was determined by changes in tracheal and bronchial distances, obtained by subtracting supine measurements from lateral measurements and subtracting measurements at start of surgery from measurements at the end of surgery, respectively. Clinically significant displacement was defined when the DLT was deviated by more than 10 mm from the initial correct position, regardless of the direction of displacement. (NCT02691468)
Timeframe: from supine to lateral decubitus position during surgery

InterventionParticipants (Count of Participants)
PVC DLT17
Silicon DLT18

[back to top]

the Incidence of Critical Malposition of DLTs

The displacement of DLT was determined by changes in tracheal and bronchial distances, obtained by subtracting supine measurements from lateral measurements and subtracting measurements at start of surgery from measurements at the end of surgery, respectively. The critical malposition was defined when the DLT was required repostion for successful OLV during position change (NCT02691468)
Timeframe: from supine to lateral decubitus position

Interventionparticipants (Number)
PVC DLT4
Silicon DLT4

[back to top]

Change in The Aberrant Behavior Checklist (ABC) From Baseline at Week 8

"The ABC is a 58-item parent rating on a 0-3 scale with five subscales:~Irritability (includes agitation, aggression, and self-injury, 15 items) with range of scores from 0-45~Social Withdrawal (16 items) with range of scores from 0-48~Stereotypies (7 items) with range of scores from 0-21~Hyperactivity (16 items) with range of scores from 0-48~Inappropriate Speech (4 items) with range of scores from 0-12.~Higher scores are worse for the ABC subscale, hence a negative estimate means more improvement with the probiotics compared to control." (NCT02903030)
Timeframe: Baseline and Week 8 of Both the First and Second Intervention

,
InterventionUnits on a scale (Mean)
ABC (1) IrritabilityABC (2) LethargyABC (3) StereotypyABC (4) HyperactivityABC (5) Inappropriate Speech
Placebo-3.50-2.50-1.80-5.40-0.10
Visbiome-1.80-2.60-1.20-2.10-0.40

[back to top]

Children's Sleep Habits Questionnaire (CSHQ) at Week 8

It includes 33 items rated retrospectively over the previous week by parents yielding a total score and eight subscales. Eight subscales include: (1) bedtime resistance (2) sleep onset latency, (3) sleep duration, (4) anxiety around sleep, (5) night awakenings, (6) sleep disordered breathing, (7) parasomnias and (8) morning waking/daytime sleepiness.Total score (summed) range of 0-99. A higher score is a better outcome for this measure. (NCT02903030)
Timeframe: Week 8 of Both the First and Second Intervention

InterventionUnits on a scale (Mean)
Visbiome42.80
Placebo43.44

[back to top]

Change in The Parenting Stress Index Short Form (PSI)

The PSI is used to evaluate the degree of stress in the parent-child relationship. The Short Form has 36 items from the full length PSI, rated on a 5-point scale from 1 = strongly disagree, to 5 = strongly agree. It is completed in 10-15 minutes. The PSI may be used for parents of children up to 12 years. It yields a Total Score and three domain scores. This will detect effect on parental stress and QOL. Higher scores (ranging from 0-180) are worse for PSI, hence a negative estimate means more improvement with the probiotics compared to control. (NCT02903030)
Timeframe: Baseline and Week 8 of Both the First and Second Intervention

InterventionUnits on a scale (Mean)
Visbiome-9.60
Placebo-1.70

[back to top]

Change in Target Symptom Rating From Baseline at Week 8

Parents are asked to name the 2 problems of most concern to them at baseline; a clinician helps the parent quantify and describe the problem (frequency, duration, severity, interference with daily life) at baseline. At subsequent visits the clinician reminds the parent of the previous description and helps them again quantify/describe the current state. A panel of blind clinicians reviews the descriptions and rates each on a 9-point scale relative to baseline, from remission (0) to disastrously worse (9), with 5=no change. These ratings are averaged, capturing the issues of most concern to parents across families. For purposes of this study, one of the 2 problems will be required to pertain to GI function, and will be analyzed separately as well as being averaged into the overall symptom rating. (NCT02903030)
Timeframe: Baseline and Week 8 of Both the First and Second Intervention

InterventionUnits on a scale (Mean)
Visbiome-2.10
Placebo-0.60

[back to top]

Change in Social Responsiveness Scale (SRS) From Baseline at Week 8

This 65-item rating scale measures the severity of autism spectrum symptoms as they occur in natural social settings. The SRS provides a clear picture of a child's social impairments, assessing social awareness, social information processing, capacity for reciprocal social communication, social anxiety/avoidance, and autistic preoccupations and traits. It is appropriate for use with children from 4 to 18 years of age and will detect changes in core ASD symptoms. A higher score in this scale represents worse symptoms with raw scores summed and generated t-scores ranging from 0-110. (NCT02903030)
Timeframe: Baseline and Week 8 of Both the First and Second Intervention

InterventionUnits on a scale (Mean)
Visbiome-4.70
Placebo-1.70

[back to top]

Change in Parent Anxiety Checklist--ASD From Baseline at Week 8

A 25-item single-factor scale measure of emotional stability/anxiety. Higher scores are worse for PRAS-ASD subscale, hence a negative estimate means more improvement with the probiotics compared to control. Scores range from 0-75. (NCT02903030)
Timeframe: Baseline and Week 8 of Both the First and Second Intervention

InterventionUnits on a scale (Mean)
Visbiome-6.20
Placebo-4.10

[back to top]

Change in Gastrointestinal (GI) Module of the Pediatric Quality of Life Inventory (PedsQL) at From Baseline at Week 8

A 74-item survey with 14 scales. Report forms for specific age ranges assess the parent's perception of the child's GI function and/or symptoms during the last month on a 5-point scale from 0 (never a problem) to 4 (almost always a problem). Items are reverse-scored and transformed to a 0-100 scale so lower scores reflect worse GI dysfunction. Response choices are in Likert-scale format ranging from 0 to 4 (0=Never, 1=Almost Never, 2=Sometimes, 3=Often, 4=Almost Always). (NCT02903030)
Timeframe: Baseline and Week 8 of Both the First and Second Intervention

InterventionUnits on a scale (Mean)
Visbiome17.97
Placebo7.98

[back to top]

VAS Scale (0-100mm)

Pain level before, during and after dressing removal. A visual analog scale (VAS) was used by the subjects to assess pain, with a range from 0 to 100, where 100 indicates the worst possible pain. (NCT02904200)
Timeframe: 0-12 days. Visit 1 (baseline), Visit 2 (day 4), Visit 3 (day 7), Visit 4 last visit (day 12)

Interventionscore on a scale (0-100) (Number)
Visit 1: Pain before application of NPWTVisit 2: Pain BEFORE removal of the covering filmVisit 2: Pain DURING removal of the covering filmVisit 2: Pain AFTER removal of the covering filmVisit 2: Pain BEFORE removal of the foam fillerVisit 2: Pain DURING removal of the foam fillerVisit 2: Pain AFTER removal of the foam fillerVisit 3: Pain BEFORE removal of the covering filmVisit 3: Pain DURING removal of the covering filmVisit 3: Pain AFTER removal of the covering filmVisit 3: Pain BEFORE removal of the foam fillerVisit 3: Pain DURING removal of the foam fillerVisit 3: Pain AFTER removal of the foam fillerVisit 4: Pain BEFORE removal of the covering filmVisit 4: Pain DURING removal of the covering filmVisit 4: Pain AFTER removal of the covering filmVisit 4: Pain BEFORE removal of the foam fillerVisit 4: Pain DURING removal of the foam fillerVisit 4: Pain AFTER removal of the foam filler
Avance® Film With Safetac®3227252219121025541717469

[back to top]

Changes on Peri-Wound Skin

"The primary objective of this investigation is to evaluate changes on Peri-Wound skin from baseline to termination when using two different wound dressings. The primary endpoint could not be calculated as intended because the baseline score was not evaluable due to missing values for the one subject that completed follow up. The primary outcome is therefore presented at 12 days. The total of the five scores provide a range from 0 to 15, with higher scores indicating a worse outcome.~The primary endpoint was assessed through the change in the sum of Peri-Wound Skin outcome scores (0-15) collected at each visit (Visit 1 (baseline), Visit 2 (day 4), Visit 3 (day 7), Visit 4 last visit (day 12)) from baseline to termination. The sum of scores will be obtained from five separate data scores, Redness/Irritation, Flaky, Maceration, Blistering, Skin tears, which will be scored separately with a value between 0 and 3 (None=0, Mild=1, Moderate=2, Severe=3)." (NCT02904200)
Timeframe: Visit 4 last visit (day 12)

Interventionscore on a scale (Number)
Avance® Film With Safetac®3

[back to top]

Compliance Rate

Percent of patients administered the investigational production who discontinued the study (NCT03633344)
Timeframe: From randomisation up to 5 days

InterventionParticipants (Count of Participants)
Carbowhite0
Carbowhite Placebo0

[back to top]

Duration of Treatment

Mean duration of treatment (NCT03633344)
Timeframe: From randomisation up to 5 days

Interventiondays (Mean)
Carbowhite1.7
Carbowhite Placebo2.6

[back to top]

Quantity of Used Medication

Mean quantity of tablets per treatment course (NCT03633344)
Timeframe: From randomisation up to 5 days

Interventiontablets (Median)
Carbowhite12
Carbowhite Placebo36

[back to top]

Reduction in Frequency of Defecation to 3 Times Per Day

Percent of patients administered the investigational production who achieved the efficacy endpoint (reduction in frequency of defecation to 3 times per day, absence of loose stool) on Day 5 or earlier (NCT03633344)
Timeframe: From randomisation up to 5 days

InterventionParticipants (Count of Participants)
Carbowhite118
Carbowhite Placebo24

[back to top]

Subjective Feedback on the Perceived Improvement of Actual Device Fitting Using Each Impression Procedure Compared to a Non-custom Hearing Aid Fitting

"Each participant answered the question at the end of each procedure- Compared to a non-custom fitting, do you feel that the method of impression/scanning improves the hearing aid process for you?, and rated on a scale from 1 (very improved) to 5 (much worse)." (NCT05000047)
Timeframe: Day one

Interventionscore on a scale (Mean)
3D Scanning Technology1.77
Conventional Silicone Impression Procedure2.13

[back to top]

Subjective Feedback of Overall Experience of Both Ear Impression Procedures

"Each participant answered the question How do you rate your experience of the recently performed ear canal impression/scanning? after each procedure. Participants rated their overall experience on a scale from 1 (worst) to 5 (best)." (NCT05000047)
Timeframe: Day one

Interventionscore on a scale (Mean)
3D Scanning Technology4.6
Conventional Silicone Impression Procedure3.9

[back to top]

Sub-investigator Clinician Subjective Rating of Individual Potential for Improvement When Performing Each Procedure 1 (no Potential for Improvement) to 3 (a Lot of Potential for Improvement)

"Sub-investigators answered a question after each procedure on each participant they saw- Do you feel like there was any potential for improvement when performing this procedure?. Each sub-investigator rated their own potential for improvement on a scale from 1(no potential for improvement, clinician was very satisfied with impression) to 3 (a lot of potential for improvement, clinician felt impression was inferior)." (NCT05000047)
Timeframe: Day 1

Interventionscore on a scale (Mean)
3D Scanning Technology1.6
Conventional Silicone Impression Procedure1.2

[back to top]

Sub-investigator Clinician Subjective Rating of Individual Confidence That Method of Impression Will Yield a Quality Custom Product for the Participant on a Scale From 1 (Not at All Confident) to 3 (Very Confident).

"Sub-investigators answered a question after each procedure on each participant they saw- How confident are you that the method of impression/scanning will yield a quality custom product? on a scale from 1 (not at all confident) to 3 (very confident)." (NCT05000047)
Timeframe: Day 1

Interventionscore on a scale (Mean)
3D Scanning Technology2.6
Conventional Silicone Impression Procedure2.9

[back to top]

Sub-investigator Clinician Subjective Rating of Ease of Procedure on a Scale From 1 (Not at All Easy) to 10 (Most Ease)

"Sub-investigators answered a question after each procedure on each participant- How easy was it to perform the procedure? on a scale from 1 (not at all easy) to 10(most ease)." (NCT05000047)
Timeframe: Day 1

Interventionscore on a scale (Mean)
3D Scanning Technology8.13
Conventional Silicone Impression Procedure9.27

[back to top]

Clinician Subjective Rating of Overall Experience of Each Procedure.

"Clinicians answered a question after each procedure on each participant they saw- How would you rate the overall experience of performing this procedure? using a scale from 1 (worst) to 5 (best)." (NCT05000047)
Timeframe: Day 1

Interventionscore on a scale (Mean)
3D Scanning Technology4.2
Conventional Silicone Impression Procedure4.5

[back to top]

Elapsed Time in Minutes to Complete Bilateral Ear Impressions

The total time in minutes, required for sub-investigators to complete each impression methodology on each participant, according to a standard of care procedure . For the silicone impressions, time was started after otoscopy and cerumen management of both ears, and just before prepping and placing the otoblocks. The timer stopped after the audiologist was satisfied with both ear impressions and placed them in box. For the ear scan, time was started after otoscopy of both ears, and just before prepping the headset and hand-held scanner. The timer stopped after the 3D scan was reviewed for each ear and audiologist satisfied with result. The time reported is how long it took for clinician to finish one complete set of impressions, which included a right and a left ear impression. Separate times for each ear was not recorded. (NCT05000047)
Timeframe: Day one

InterventionMinutes (Mean)
Set of Ear Impressions Taken Using 3D Scanner8.15
Set of Impressions Taken Using Traditional Silicone Ear Impression Material and Technique6.28

[back to top]

Subjective Feedback, Pleasantness of Experience

"Each participant answered the question How pleasant do you rate the impression/scanning procedure? after each procedure. Participants rated the the pleasantness on a scale from 1 (very pleasant) to 5 (very unpleasant)." (NCT05000047)
Timeframe: Day one

Interventionscore on a scale (Mean)
3D Scanning Technology1.73
Conventional Silicone Impression Procedure2.4

[back to top]